Introduction {#s1}
============

Dilated cardiomyopathy (DCM) is a common and irreversible type of heart disease. It is the third most common case of heart failure and the most frequent cause for heart transplantation ([@bib3]) with an estimated prevalence of 40 in 100.000 people ([@bib46]). Up to 80% of DCM patients present heart failure symptoms ([@bib21]). Frequently, the disease first affects the left ventricle, where the muscle starts to remodel, leading to increased end-diastolic and end-systolic volumes ([@bib49]).

The heart is a highly vascularized organ and capillaries reside in close proximity to almost every cardiomyocyte with a cellular ratio between cardiomyocytes and endothelial cells (ECs) of 1:3 ([@bib11]; [@bib34]). Around 35% of the known cases of DCM are due to mutations in genes that mainly encode myocardial cytoskeletal, sarcomeric and nuclear envelope proteins, but there are also acquired causes that include metabolic and endocrine disruptions ([@bib26]; [@bib83]). Yet, most of the DCM cases are considered idiopathic, as the underlying cause is unknown ([@bib74]). Capillary ECs constitute a functional interface between the circulation and the myocardium. Their proximity to cardiomyocytes makes ECs ideally suited to control cardiac muscle cell homeostasis by, for example, the regulation of nutrient delivery and organ metabolism. Fatty acids are a crucial metabolic substrate for the heart ([@bib76]) and alterations in cardiomyocyte nutrient preference, such as enhanced glucose uptake and glycolysis, have been observed in multiple pathological conditions ([@bib60]). Highlighting the importance of ECs in cardiac homeostasis, endothelial mutations in the laminin α4 subunit and integrin-linked kinase can cause cardiomyopathy ([@bib38]) and disruption of endothelial Notch signaling impairs fatty acid transport and leads to pathological heart remodeling ([@bib36]).

The receptor tyrosine kinase EphB4 and its ligand, the transmembrane protein ephrin-B2, regulate critical aspects of EC behavior in a cell-cell contact-dependent fashion. Signaling by ephrin-B2 and EphB4 has been implicated in the regulation of sprouting angiogenesis, vascular morphogenesis, arteriovenous differentiation ([@bib57]), and cancer ([@bib56]), but little is known about the function of this ligand-receptor pair in adult organ homeostasis. Here, we report that inducible inactivation of the *Ephb4* gene in the adult endothelium causes a cardiac phenotype that resembles key features of DCM. Mutant ECs are prone to break upon mechanical stress and are not able to transport fatty acids resulting in cardiomyocyte hypertrophy and heart remodeling similar to defects observed in dilated cardiomyopathy. Our results identify ephrin-B2 and EphB4 as critical regulators of the cardiac vasculature and heart homeostasis.

Results {#s2}
=======

Loss of endothelial EphB4 causes heart hypertrophy {#s2-1}
--------------------------------------------------

The receptor tyrosine kinase EphB4 and its ligand ephrin-B2 are expressed in the capillary plexus of the adult coronary vasculature. In addition, EphB4 is expressed in large veins, whereas ephrin-B2 is restricted to arteries ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). To determine the role of signaling by EphB4 and ephrin-B2 in the adult cardiac endothelium, we bred mice bearing a conditional *Ephb4* loss-of-function allele ([@bib82]) with *Cdh5^CreERT2^* ([@bib81]) transgenic animals expressing tamoxifen-inducible Cre recombinase specially in ECs. Following the injection of adult mice at 8 weeks of age with 4-hydroxy tamoxifen, hearts were analyzed 4 weeks afterwards. Cre activity was monitored using *R26-mTmG* Cre reporter mice ([@bib51]), in which all cells express membrane-anchored Tomato fluorescent protein but switch to the expression of membrane-associated green fluorescent protein (GFP) in a Cre-controlled fashion. This approach revealed a very high recombination efficiency in cardiac ECs at 12 weeks ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Moreover, EphB4 expression was strongly diminished in the coronaries of *Cdh5^CreERT2^ Ephb4^flox/flox^* (Ephb4^∆EC^) hearts when compared to Cre-negative littermate controls ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). This result was further confirmed by the drastic reduction of EphB4 protein in Ephb4^∆EC^ whole heart lysates analyzed by Western blot ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}).

Morphometric characterization revealed that heart size and weight were increased in Ephb4^∆EC^ mutants. On average, mutant hearts weighed 20% more than controls, whereas total body weight was not significantly altered. Normalization of heart weight to tibia length ([@bib86]) confirmed this finding ([Figure 1A](#fig1){ref-type="fig"}). Histologic analysis of the left ventricle's cardiac wall revealed a significant enlargement of the cardiomyocytes in Ephb4^∆EC^ hearts ([Figure 1B](#fig1){ref-type="fig"}), indicating hypertrophic remodeling of the heart muscle. Moreover, echocardiography analysis of mutant hearts showed a reduced heart ejection fraction and larger left ventricle diastolic and systolic volumes ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---videos 1](#fig1video1){ref-type="video"} and [2](#fig1video2){ref-type="video"}). Cardiac magnetic resonance imaging (CMRI) revealed that the walls of the organ were significantly thinner at the interventricular septum and that the mass of the left ventricle was lower, whereas the right ventricle was not affected at this stage ([Figure 1D](#fig1){ref-type="fig"} and [Figure 1---videos 3](#fig1video3){ref-type="video"}--[6](#fig1video6){ref-type="video"}). These observations indicate ongoing dilation of Ephb4^∆EC^ mutant ventricles.

![Heart defects in adult *Ephb4* mutants.\
(**A**) Freshly dissected Ephb4^∆EC^ and littermate control hearts at 12 weeks of age. Heart weight and heart weight/tibia length index (HW/TL) ratio are increased in Ephb4^∆EC^ mutants, whereas body weight remains unchanged. N = 5 for control and N = 8 for Ephb4^∆EC^. (**B**) Immunohistochemistry on cross sections of control and Ephb4^∆EC^ hearts at 12 weeks. Panels show the inner part of the left ventricular wall with significantly increased cardiomyocyte relative area in Ephb4^∆EC^ samples. N = 4 for both genotypes. (**C**) Echocardiography analysis of 12 week-old animals. Ejection fraction (EF) is significantly reduced in mutant mice while left ventricle diastolic and systolic volumes are increased. lv, left ventricle. N = 10 for control and N = 6 for Ephb4^∆EC^ (**D**) CMRI sections of hearts showing four-chamber (left) and short axis (right) views of control and Ephb4^∆EC^ at 12 weeks of age. Arrowheads indicate the ventricular septum and the wall of the left ventricle. rv, right ventricle; lv, left ventricle. Ventricular septum thickness and left ventricular (lv) mass are significantly reduced in Ephb4^∆EC^ mice, whereas right ventricular (rv) mass remains unchanged. N = 9 for control and N = 11 for Ephb4^∆EC^. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction. ns, not significant.\
Figure 1---source data 1.Source data for [Figure 1A,B,C,D](#fig1){ref-type="fig"}.](elife-45863-fig1){#fig1}

Loss of EphB4 affects the stability of the coronary plexus {#s2-2}
----------------------------------------------------------

Next, we examined the cell-autonomous effects of *Ephb4* inactivation in coronary vessels. Interestingly, histologic analysis revealed that mutant mice have reduced vascular density with less coronary vessel branch points ([Figure 2A](#fig2){ref-type="fig"}), an effect that could be partially influenced by the increased cardiomyocyte area. In addition, immunostaining against PDGFRβ, a marker of pericytes and vascular smooth muscle cells associated with the endothelial monolayer, showed a significant loss of mural cell coverage in the blood vessels of the ventricle, which was especially prominent in certain capillaries ([Figure 2B](#fig2){ref-type="fig"}). Moreover, extravasated erythrocytes were detected in the mutant myocardium, indicating the presence of microhemorrhages in the Ephb4^∆EC^ ventricular wall ([Figure 2C](#fig2){ref-type="fig"}). Nevertheless, mutant ECs did not show increased cell death, as indicated by comparable TUNEL staining in control and mutant ventricles ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Analysis of tissue oxygenation through Pimonidazole administration did not indicate appreciable tissue hypoxia, arguing for sufficient oxygen transport through the Ephb4^∆EC^ endothelium ([Figure 2---figure supplement 1B,C](#fig2s1){ref-type="fig"}). It is also noteworthy that loss of EphB4 in ECs did not induce fibrosis in the mutant myocardium ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}).

![*Ephb4* inactivation compromises cardiac vascular integrity.\
(**A--C**) Immunostaining of cross sections through 12 week-old control and Ephb4^∆EC^ hearts. Confocal images show the outer (**A, C**) and inner part (**B**) of the left ventricle. (**A**) Vascular density, measured by number of branching points, is significantly reduced in Ephb4^∆EC^ samples. N = 3 for control and N = 6 for Ephb4^∆EC^. (**B**) Pericyte coverage is reduced in Ephb4^∆EC^ hearts (arrowheads mark affected capillaries). N = 3 per genotype. (**C**) Presence of microhemorrhages (arrowheads mark erythrocytes in the mutant myocardium). (**D**) Electron micrographs of control and Ephb4^∆EC^ capillaries. Bottom images are higher magnifications of boxed areas in upper panels. White arrowheads indicate accumulation of caveolar vesicles at the mutant endothelial basolateral membrane (center) and thrombocytes in a vascular rupture (right). Yellow arrowheads indicate mitochondrial glycogen accumulation. Erythrocytes (er), thrombocytes (th), cardiomyocytes (cm) and endothelial cells (ec) are indicated. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction.\
Figure 2---source data 1.Source data for [Figure 2A,B](#fig2){ref-type="fig"}.](elife-45863-fig2){#fig2}

To study the phenotype of Ephb4^∆EC^ ECs in more detail, we analyzed the vasculature of the left ventricular wall by transmission electron microscopy (TEM). High magnification images revealed that mutant ECs were irregularly arranged and displayed an expanded cytoplasm largely devoid of vesicles, whereas caveolar structures were abundant along the basolateral membrane ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 3A--C](#fig2s3){ref-type="fig"}). Moreover, mutant cardiomyocytes showed the accumulation of glycogen granules in their cytoplasm close to the mitochondria ([Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). These observations suggest that the transport through the endothelium and cardiomyocyte metabolism might be affected in Ephb4^∆EC^ mutant hearts. TEM also revealed ruptures of the capillaries explaining the microhemorrhages mentioned above ([Figure 2D](#fig2){ref-type="fig"}).

Inactivation of the gene encoding ephrin-B2 in adult ECs {#s2-3}
--------------------------------------------------------

To address the role of ephrin-B2 in EphB4-mediated signaling, we interbred mice bearing a conditional *Efnb2* loss-of-function allele, *Efnb2^flox/flox^* ([@bib32]) with *Cdh5^CreERT2^* transgenic mice and treated *Cdh5^CreERT2^ Efnb2^flox/flox^* (Efnb2^∆EC^) mice and Cre-negative littermate controls with 4-hydroxy tamoxifen in the same way as described above for Ephb4^∆EC^ mutants. The phenotype observed upon EC-specific loss of ephrin-B2 was milder than the defects in Ephb4^∆EC^ hearts. While Efnb2^∆EC^ heart weight was not altered ([Figure 3A](#fig3){ref-type="fig"}), the cardiomyocyte relative area was significantly increased ([Figure 3B](#fig3){ref-type="fig"}). Vascular density ([Figure 3C](#fig3){ref-type="fig"}) and perivascular coverage of the capillaries ([Figure 3D](#fig3){ref-type="fig"}) was not appreciably altered. Interestingly, the changes observed in Efnb2^∆EC^ mutants were very similar to the ones seen in Ephb4^∆EC^ hearts at 10 weeks of age, that is 2 weeks after tamoxifen induction. Ephb4^∆EC^ hearts at this stage did not show yet a significant weight increase ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) but their cardiomyocytes were already hypertrophic, resulting in a significant increase in relative area ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Ephb4^∆EC^ vascular density ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) and perivascular coverage of the capillaries ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}) was not yet affected at 10 weeks. Both, Efnb2^∆EC^ hearts at 12 weeks and Ephb4^∆EC^ hearts at 10 weeks hearts presented microhemorrhages ([Figure 3---figure supplement 2A,B](#fig3s2){ref-type="fig"}).

![Heart phenotype after *Efnb2* inactivation in the vascular endothelium.\
(**A**) Efnb2^∆EC^ and littermate control hearts at 12 weeks of age. Heart weight and heart weight/tibia length index (HW/TL) remain unaffected in Efnb2^∆EC^ mutants. N = 6 for control and N = 5 for Efnb2^∆EC^. (**B--D**) Immunohistochemistry on sections of control and Efnb2*^ΔEC^* hearts. Panels show the inner (**B, D**) and the outer part (**C**) of the wall of the left ventricle. (**B**) Cardiomyocyte (CM) relative area is significantly increased in Efnb2^∆EC^ hearts. N = 4 for control and N = 3 for Efnb2^∆EC^. (**C**) Vascular density, measured by number of branching points, remains unchanged in Efnb2^∆EC^ samples. N = 4 for control and N = 3 for Efnb2^∆EC^. (**D**) Cardiac pericyte coverage is not reduced in Efnb2^∆EC^ mutants. N = 4 for control and N = 3 for Efnb2^∆EC^. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction. ns, not significant.\
Figure 3---source data 1.Source data for [Figure 3A,B,C,D](#fig3){ref-type="fig"}.](elife-45863-fig3){#fig3}

Heart-specific muscle cell remodeling after loss of EphB4 in ECs {#s2-4}
----------------------------------------------------------------

To investigate whether the observed muscle cell defects are confined to heart, we analyzed skeletal muscle, a tissue where EphB4 and ephrin-B2 are expressed in the vasculature in a similar pattern as in heart ([Figure 4A](#fig4){ref-type="fig"}). In contrast to the defects seen in cardiac muscle, skeletal muscle was unaffected after the EC-specific inactivation of *Ephb4*. Both vascular density ([Figure 4B](#fig4){ref-type="fig"}) and pericyte coverage ([Figure 4C](#fig4){ref-type="fig"}) of capillaries remained unchanged and, most importantly, the relative area occupied by myocytes was not significantly altered ([Figure 4D](#fig4){ref-type="fig"}). Likewise, the vasculature of other organs, namely kidney and liver, was not appreciably altered in EphB4^∆EC^ mutants ([Figure 4---figure supplement 1A--C](#fig4s1){ref-type="fig"}).

![EphB4 inactivation does not affect the skeletal muscle.\
(**A--D**) Immunohistochemistry on longitudinal sections of control and Ephb4^∆EC^ gastrocnemius at 12 weeks of age. (**A**) EphB4 and ephrin-B2 (GFP in *Efnb2::GFP* reporter line) are expressed in capillaries (arrowheads). (**B**) Vascular density, measured by number of branching points, is not changed in Ephb4^∆EC^ gastrocnemius. (**C**) Pericyte coverage and (**D**) myocyte (M) relative area is not reduced in Ephb4^∆EC^ gastrocnemius. N = 3 for both genotypes. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction. ns, not significant.\
Figure 4---source data 1.Source data for [Figure 4B,C,D](#fig4){ref-type="fig"}.](elife-45863-fig4){#fig4}

EphB4 mutations are known to cause *hydrops fetalis* ([@bib47]) due to the role of EphB4 in the development of lympho-venous valves ([@bib88]). In order to rule out that the Ephb4^∆EC^ phenotype is caused by defects in lymphatic vessels, which are also targeted by *Cdh5^CreERT2^* transgenic allele, we interbred *Ephb4* conditional mice with *Prox1^CreERT2^* animals ([@bib8]). Despite efficient EphB4 deletion in lymphatic vessels (Ephb4^∆LEC^) after 4-hydroxy tamoxifen administration ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}), heart size and cardiomyocyte relative area remained unaffected ([Figure 4---figure supplement 2B,C](#fig4s2){ref-type="fig"}). These results argue that the heart phenotype arises due to loss of EphB4 in blood vessels but not the lymphatic vasculature.

Gene expression analysis indicates EphB4-dependent metabolic defects {#s2-5}
--------------------------------------------------------------------

To gain insight into the molecular processes occurring in Ephb4^∆EC^ mutant hearts, we performed global gene expression analysis of mutant and littermate control ventricles at 12 weeks of age by RNA sequencing. Differential gene expression analysis identified 529 genes (p\<0.05) of which 268 were upregulated and 261 downregulated ([Figure 5A](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Gene ontology (GO) classification of differentially expressed genes was calculated using the database Enrichr (<http://amp.pharm.mssm.edu/Enrichr/>) ([@bib14]; [@bib39]) ([Figure 5B--F](#fig5){ref-type="fig"}). First, the analysis revealed that genes related to human disease, and in particular to coronary artery disease, hypertrophic cardiomyopathy (HCM) and DCM were dysregulated in Ephb4^∆EC^ hearts ([Figure 5B](#fig5){ref-type="fig"}). Further GO analysis of biological processes revealed that genes related to the regulation of carbohydrate metabolism and the positive regulation of glycolysis were upregulated in mutant samples. These observations are interesting because glucose consumption and glycolysis in the heart are indicators of cardiomyopathy ([@bib60]) ([Figure 5C](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). We also observed that genes related to extracellular matrix (ECM) organization were downregulated in Ephb4^∆EC^ hearts ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) returned several interesting pathways enriched in affected genes. In particular, two signaling pathways strongly related to cardiac metabolism and disease were altered: FoxO signaling and the genes *Agap2*, *Pten*, *Igf1*, *Pik3r1*, *Foxo3* and *Pck2* were upregulated, whereas mTOR signaling and the genes *Irs1*, *Rragd*, *Hif1a* and *Vegfa* were downregulated in mutant hearts ([Figure 5E,F](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}) ([@bib61]; [@bib66]; [@bib67]; [@bib87]).

![RNA-seq analysis of total heart suggests a metabolic shift in *Ephb4* mutants.\
(**A--F**) Global gene expression analysis of Ephb4^∆EC^ ventricles by RNA sequencing at 12 weeks. (**A**) MA plot representing the 529 differentially expressed genes (p\<0.05) including 268 upregulated genes (red) and 261 downregulated genes (blue). (**B--F**) Representation of the ten most significant functional categories in each group revealed by gene ontology analysis using the Enrichr data base. Graphs represent Enrichr combined score that combines *P* value and Z score. Numbers in brackets represent the number of differentially expressed genes in the corresponding category. (**B**) Human disease enriched terms according to the Online Mendelian Inheritance in Man (OMIM). Biological processes upregulated (**C**) and downregulated (**D**) in Ephb4^∆EC^ ventricles. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways upregulated (**E**) and downregulated (**F**) in Ephb4^∆EC^ ventricles. HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy.\
Figure 5---source data 1.RNA-seq analysis of Ephb4^∆EC^ and control mouse heart ventricles.The table indicates all the transcripts significantly upregulated and downregulated in *Ephb4* mutant hearts.\
Figure 5---source data 2.Global proteome analysis of Ephb4^∆EC^ and control mouse heart ventricles.The table indicates all the proteins significantly upregulated and downregulated in *Ephb4* mutant hearts.](elife-45863-fig5){#fig5}

To gain a more complete overview of the alterations in Ephb4^∆EC^ hearts, we analyzed the changes at the protein level by mass spectrometry of ventricles relative to littermate controls ([Figure 5---figure supplement 1D--G](#fig5s1){ref-type="fig"}). This revealed a total of 455 significant altered proteins (p\<0.05), of which 206 were upregulated and 249 downregulated ([Figure 5---figure supplement 1E](#fig5s1){ref-type="fig"} and [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}). Remarkably, GO analysis of biological processes in the mutant ventricles revealed an upregulation of metabolic processes ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}) accompanied by downregulation of endocytic recycling ([Figure 5---figure supplement 1G](#fig5s1){ref-type="fig"}). Altogether these results suggest that cardiac remodeling in Ephb4^∆EC^ mutants is linked to defective transport processes and a metabolic shift towards glycolysis in heart.

EphB4 controls caveolar function and fatty acid uptake {#s2-6}
------------------------------------------------------

Pathways implicated in signal transduction downstream of EphB4, such as signaling through Phosphoinositide 3-kinase (PI3K)-Akt ([@bib69]), mitogen-activated protein kinase (MAPK)/ERK ([@bib18]) and Src ([@bib85]), are also known to regulate intercellular vesicular trafficking ([@bib10]). In cultured human umbilical vein endothelial cells (HUVECs), stimulation with recombinant and soluble ephrin-B2/Fc protein induces phosphorylation of Akt and Src, which is blocked by the pathway-specific inhibitors LY294002 and PP2, respectively ([Figure 6A,B](#fig6){ref-type="fig"}). In contrast, levels of phosphorylated ERK1/2 were reduced after ephrin-B2/Fc treatment. Stimulation with EphB4/Fc, which is known to activate signaling through the cytoplasmic domain of ephrin-B2 ([@bib54]), led to activation of Src but not of Akt and ERK1/2 in cultured HUVECs ([Figure 6A,B](#fig6){ref-type="fig"}). We also noted overlap between EphB4 receptor, detected by binding of ephrin-B2/Fc, and phosphorylated caveolin 1 (CAV1) ([Figure 6C](#fig6){ref-type="fig"}), an integral membrane protein in caveolar membranes and regulator of caveolae-mediated endocytosis. Interestingly, previous work has linked phosphorylation of caveolin to Src kinase ([@bib40]; [@bib71]).

![EphB4-induced signaling in cultured ECs.\
(**A**) Western blot analysis of lysates from cultured HUVECs stimulated with control human IgG/Fc (Ctrl Fc), human ephrin-B2/Fc (B2/Fc) or mouse EphB4/Fc (B4/Fc) (4 µg/ml, preclustered with 10µg/ml goat anti-human IgG), concurrently treated with inhibitors (LY294002, U0126, PP2) or DMSO for 30 min. Active Src (pSrc) was determined by anti-Src immunoprecipitation (IP) followed by anti-Src or anti-phosphotyrosine (4G10) immunoblotting. Bottom panel indicates Src input in total cell lysate (TL). Molecular weights (kDa) are indicated. N = 3 for all treatments. (**B**) Graphs show relative quantitation of pAkt/Akt, pERK1/2/ERK1/2, pSrc/Src and pSrc/Src/input. N = 3 for LY294002 and U0126 experiments. For PP2 experiment N = 4 for Ctrl Fc/DMSO, B4/Fc/DMSO and B4/Fc/PP2 and N = 5 for all the other conditions. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA with Sidak's multiple comparisons test. (**C**) Colocalization (arrowheads) of EphB4 (green) and phospho-CAV1 (pCAV1, red) in HUVECs 30 min after stimulation with human IgG/Fc or ephrin-B2-Fc. Rightmost panels show higher magnification of selected areas. Cell junctions, VE-Cadherin (CDH5, white); nuclei, DAPI (blue). ns, not significant.\
Figure 6---source data 1.Source data for [Figure 6B](#fig6){ref-type="fig"}.](elife-45863-fig6){#fig6}

Next, we treated HUVECs with an siRNA against *EPHB4 (siEPHB4)* or an unrelated negative control. Transfection of *siEPHB4* efficiently abolished expression of the receptor tyrosine kinase at protein level, as assessed by Western blotting ([Figure 7A,C](#fig7){ref-type="fig"}). Knockdown of *EPHB4* also resulted in significant reductions of phospho-Src and phosphorylated CAV1, the latter of which was also profoundly reduced in HUVECs treated with *siCAV1* siRNA ([Figure 7A--C](#fig7){ref-type="fig"}). CAV1 and phospho-CAV1 immunostaining decorate the cytoplasm and the Golgi apparatus, identified by anti-GM130 antibody signal, and both CAV1 and phospho-CAV1 were significantly reduced after knockdown of *EPHB4* or *CAV1* ([Figure 7D,E](#fig7){ref-type="fig"}). *siEPHB4* or *siCAV1* transfection of HUVECs also led to a significant increase in cell size ([Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}).

![Alterations after knockdown of *EPHB4* expression in ECs.\
(**A**) Western blot analysis of HUVECs transfected with *siControl*, *siEPHB4* or *siCAV1*, as indicated. Knockdown cells showed a reduction of CAV1 and pCAV1 protein levels. N = 3 for all treatments. (**B**) Src input total cell lysate (TL) and tyrosine phosphorylation of immunoprecipitated (IP) Src in siRNA-treated HUVECs. Bottom panels show levels of CD36 and GAPDH (loading control). N = 3 for all treatments. (**C**) Quantitation of immunoblots for levels of EphB4, CAV1, pCAV1, CD36, pSrc/Src and ratio of pSrc/Src/ input. N = 3 for all treatments. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA with Sidak's multiple comparisons test. (**D**) Confocal images of siRNA-transfected HUVECs stained with CAV1 or pCAV1 (red), GM130 (green), VE-Cadherin (CDH5; white) and nuclei (DAPI; blue). Bottom panels show surface CD36 (red), Phalloidin (white), and nuclei (DAPI; blue). (**E**) Quantitation of CAV1, pCAV1 and CD36 MFI per whole cell and of surface CD36 signal of immunostained HUVECs, as shown in (**D**). N = 3 experiments for CAV1 and pCAV1, in each of them 30 cells were quantified from three images (10 cells/ image). N=3 for CD36 surface staining, in which three images/experiment were quantified for all siRNA conditions. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA with Sidak's multiple comparisons test. MFI, mean fluorescence intensity; ns, not significant.\
Figure 7---source data 1.Source data for [Figure 7C](#fig7){ref-type="fig"}.\
Figure 7---source data 2.Source data for [Figure 7E](#fig7){ref-type="fig"}.](elife-45863-fig7){#fig7}

Further arguing for EphB4-induced phosphorylation of CAV1 through Src, ephrin-B2/Fc treatment of HUVECs significantly increased phospho-CAV1, which was blocked by addition of the Src family kinase inhibitor PP2 ([Figure 8A,B](#fig8){ref-type="fig"}). In contrast, EphB4/Fc treatment did not lead to appreciable changes in phospho-CAV1 ([Figure 8A,B](#fig8){ref-type="fig"}). In immunostainings, stimulation with ephrin-B2/Fc increased phospho-CAV1 signals, which was blocked by presence of PP2 ([Figure 8C--E](#fig8){ref-type="fig"}). In contrast, inhibition of PI3K-Akt with LY294002 or of MAPK/ERK with U0126 had no significant effect on CAV1 phosphorylation ([Figure 8D,E](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1C](#fig8s1){ref-type="fig"}). Treatment with ephrin-B2/Fc or EphB4/Fc alone or in combination with PP2, LY294002 or U0126 did not lead to alterations in cell size ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). Confirming that the effect of ephrin-B2/Fc is indeed mediated by EphB4 and not another member of the large Eph receptor family, the increase in CAV1 phosphorylation after ephrin-B2 stimulation was suppressed in HUVECs treated with *siEPHB4* ([Figure 8G](#fig8){ref-type="fig"}). Together, these results argue that EphB4 activation triggers the phosphorylation of CAV1 through the cytoplasmic kinase Src, which generates a molecular link to caveolar transport in ECs and provides an explanation for the observed accumulation of caveolae at the basolateral membrane of the Ephb4^∆EC^ cardiac endothelium.

![EphB4 activation induces Src-dependent phosphorylation via Src.\
(**A**) Western blot analysis of CAV1 and pCAV1 levels in HUVECs stimulated with control human IgG/Fc (Ctrl Fc), ephrin-B2/Fc (B2/Fc) or EphB4/Fc (B4/Fc) (4 µg/ml, preclustered with 10µg/ml goat anti-human IgG) in combination with DMSO (vehicle control) or the Src inhibitor PP2. GAPDH is shown as loading control. (**B, F**) Quantitation of Western blots results (see **A**) for pCAV1 together with the ratio pCAV1/CAV1 (**B**) and levels of CD36 (**F**). N = 3 for all treatments. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA with Sidak's multiple comparisons test. (**C**) Confocal images of HUVECs after stimulation with Fc proteins in combination with DMSO or PP2. Stainings show pCAV1 (red), GM130 (green), CDH5 (white) and DAPI (blue). (**D**) Ratio of pCAV1/CAV1 in lysates from HUVECs treated with ephrin-B2/Fc in combination with DMSO (vehicle control) or the indicated inhibitors (LY294002, PP2 and U0126). N = 3 for all treatments. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction. (**E**) Quantitation of pCAV1 immunosignal per cell (as shown in **C**) of HUVECs stimulated with Fc proteins along with inhibitor treatment. N = 3 experiments, in each of them 30 cells were quantified from three images (10 cells/ image) for all treatments. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA test. (**G**) Quantitation of normalized CAV1, pCAV1 and pCAV1/CAV1 in immunoblotted lysates from HUVECs treated with control *siCtrl* or *siEPHB4* in combination with Ctrl Fc or ephrin-B2/Fc (B2/Fc). N = 3 for all conditions. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA. Norm. IntDen, normalized integrated density; ns, not significant.\
Figure 8---source data 1.Source data for [Figure 8B,F](#fig8){ref-type="fig"}.\
Figure 8---source data 2.Source data for [Figure 8D](#fig8){ref-type="fig"}.\
Figure 8---source data 3.Source data for [Figure 8E](#fig8){ref-type="fig"}.\
Figure 8---source data 4.Source data for [Figure 8G](#fig8){ref-type="fig"}.](elife-45863-fig8){#fig8}

Next, we analyzed caveolae and clathrin-mediated endocytosis by assessing the uptake of fluorescent-labeled albumin and transferrin, respectively ([@bib33]; [@bib35]; [@bib41]). Flow cytometry and the analysis of stained cells revealed significant reductions in the uptake of albumin, a caveolae-dependent process, upon EphB4 downregulation ([Figure 9A,C](#fig9){ref-type="fig"} and [Figure 9---figure supplement 1A,B](#fig9s1){ref-type="fig"}). Similarly, transfection with *siCAV1* impaired the uptake of albumin ([Figure 9A,C](#fig9){ref-type="fig"}). In contrast, the clathrin-controlled uptake of transferrin was unaffected in non-permeabilized *siEPHB4* cells and slightly reduced after permeabilization and immunostaining ([Figure 9---figure supplement 1C--F](#fig9s1){ref-type="fig"}).

![EphB4 is required for caveolar transport.\
(**A**) Confocal images of HUVECs transfected *siControl*, *siEPHB4* and *siCAV1*. Cells were fixed 30 min after exposure to BSA-555 (red) and immunostained with anti-CDH5 (white) antibody and DAPI (nuclei, blue). (**B**) Confocal images of *siControl*, *siEPHB4* and *siCAV1* HUVEC cells fixed after 30 min of treatment with BODIPY C~12~-500/510 (green) and immunostained for CDH5 (white). (**C**) Quantitation of BSA-555 (top) and BODIPY C~12~-500/510 (bottom) MFI per cell in *siControl*, *siEPHB4* and *siCAV1* HUVECs. Note reduced uptake of BSA and BODIPY in *siEPHB4* and *siCAV1* cells. N = 3 experiments, in each of them 30 cells were quantified from three images (10 cells/ image) for all knockdown conditions. Data represented as mean ± s.e.m. *P* values calculated by ordinary one-way ANOVA test. (**D**) CD36 expression in 12 week-old control and Ephb4^∆EC^ sectioned heart. Panels show details of the inner part of the left ventricle. CD36 immunosignal is reduced in mutant capillaries (arrowheads) but increased in the membrane of cardiomyocytes (arrows). MFI, mean fluorescence intensity.\
Figure 9---source data 1.Source data for [Figure 9C](#fig9){ref-type="fig"}.](elife-45863-fig9){#fig9}

To address whether impairment of caveolae might affect fatty acid transport in HUVECs, we exposed cultured cells to BODIPY C~12~, a fluorescent fatty acid analog mimicking properties of natural lipids ([@bib7]). This approach revealed significantly reduced fatty acid uptake in *siEPHB4* HUVECs relative to control cells, based on both flow cytometry data and the analysis of stained cells ([Figure 9B,C](#fig9){ref-type="fig"} and [Figure 9---figure supplement 1G,H](#fig9s1){ref-type="fig"}). CD36 is a membrane receptor mediating the endocytosis of fatty acids and requires caveolar transport for its correct localization and function ([@bib59]). While immunostaining of *siEPHB4* and *siCAV1* transfected HUVECs revealed no change in total CD36 immunosignal relative to control cells ([Figure 7E](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}), surface CD36 was significantly reduced relative to control cells ([Figure 7D,E](#fig7){ref-type="fig"}). Further, CD36 localization to Golgi was increased after knockdown of *EPHB4* or *CAV1* ([Figure 7---figure supplement 1A,B](#fig7s1){ref-type="fig"}), potentially indicating CD36 synthesis and thereby a compensatory response to reduced fatty acid uptake. CD36 levels were not significantly altered after acute stimulation of HUVECs with ephrin-B2/Fc ([Figure 8F](#fig8){ref-type="fig"}). In vivo, CD36 immunosignal is downregulated in capillaries of the Ephb4^∆EC^ myocardium but appears upregulated in the membrane of cardiomyocytes, again suggesting a potential compensatory mechanism to restore fatty acid uptake ([Figure 9D](#fig9){ref-type="fig"}).

Given the known link between metabolic changes and heart remodeling in human cardiomyopathies, we also assessed metabolic changes in Ephb4^∆EC^ mice in vivo. Glucose concentration was reduced in mutant plasma relative to littermate controls, whereas levels of triglycerides and free fatty acids appeared unaffected ([Figure 9---figure supplement 2A](#fig9s2){ref-type="fig"}). Interestingly, histological analysis of Ephb4^∆EC^ livers revealed the accumulation of fat ([Figure 9---figure supplement 2B](#fig9s2){ref-type="fig"}), suggesting that defective caveolar transport and fatty acid uptake by mutant cardiac ECs is accompanied by ectopic lipid deposition in liver.

EphB4 maintains the structural integrity of the cardiac endothelium {#s2-7}
-------------------------------------------------------------------

Next, we investigated the cause of the ruptures and microhemorrhages in the Ephb4^∆EC^ cardiac endothelium. Caveolar transport is also required for the recycling and proper function of focal adhesion and cell junction proteins in ECs ([@bib52]). Moreover, the junction protein VE-Cadherin together with linker proteins, such as Vinculin, couples cell junctions to the actin cytoskeleton ([@bib1]) and thereby maintains the integrity of the EC monolayer, which is probably most relevant in environments characterized by high mechanical loading such as the heart. In cultured HUVECs, *siEPHB4* transfection reduced the accumulation and localization of focal adhesion proteins in cell junctions under static conditions, whereas VE-Cadherin localization was maintained ([Figure 10A,C](#fig10){ref-type="fig"}). When HUVECs were cultured under cyclic tension mimicking 10% of sinusoidal stretch for 24 hr, control cells were able to maintain a continuous monolayer but *siEPHB4* cells were frequently separated by large gaps ([Figure 10B,C](#fig10){ref-type="fig"}). Furthermore, atomic force microscopy (AFM) revealed that the downregulation of *EPHB4* results in decreased cell stiffness relative to control HUVECs, as indicated by a significant reduction in the Young's Module that measures membrane displacement upon force application with a cantilever ([Figure 10D](#fig10){ref-type="fig"}). Altogether, these results show that the EphB4 receptor is required for the structural integrity of cultured ECs, which may well explain the vessel wall ruptures observed in vivo.

![EphB4 is required for endothelial integrity.\
(**A**) Immunohistochemistry of cultured HUVECs. Relative colocalization of Vinculin and CDH5 is reduced in the cell contact area (arrowheads) of *siEPHB4* cells. (**B**) Mechanical stress assay on cultured HUVECs transfected with *siEPHB4*. Cells are able to form a monolayer on a membrane under static conditions. Sinusoidal stretch of the membrane disrupts the monolayer, as measured by the increase of empty area in *siEPHB4* HUVEC cells (arrowheads) (**C**). (**C**) Quantitation of relative colocalization of Vinculin and CDH5 (left). N = 3 for *siControl* and N = 5 for *siEPHB4.* Quantitation of the empty area between *siControl* and *siEPHB4* HUVECs in static conditions or with stretching (right). N = 3. Data represented as mean ± s.e.m. *P* value calculated by unpaired two-tailed *t* test with Welch's correction (left) or ordinary one-way ANOVA with Sidak's multiple comparisons test (right). (**D**) Atomic force microscopy analysis of cell stiffness. Young's modulus is reduced in *siEPHB4* cells. Each dish contains three force maps that equal 768 force-distance curves. Studied areas (150 × 150 µm) contain 10--16 cells. In between 16 and 25 force-distance curves were measured per cell. N = 4 areas. Data represented as mean ± s.e.m. *P* values calculated by unpaired two-tailed *t* test with Welch's correction. ns, not significant.\
Figure 10---source data 1.Source data for [Figure 10C,D](#fig10){ref-type="fig"}.](elife-45863-fig10){#fig10}

In conclusion, our results show the loss of EphB4 impairs the mechanical properties and transport function of ECs, which results in capillary ruptures, metabolic alterations, cardiomyocyte hypertrophic remodeling, and heart dilation.

Discussion {#s3}
==========

There is increasing evidence that blood vessels acquire organ-specific specialization ([@bib6]), which is necessary to deal with specific metabolic needs and other, typically local properties of the surrounding tissue. In the case of the beating heart, the vasculature has to resist extensive mechanical strain and needs to provide cardiomyocytes with sufficient amounts of fatty acids. We propose that these special properties of the cardiac vasculature involve interactions between the receptor tyrosine kinase EphB4 and its ligand ephrin-B2. While ephrin-B2 and EphB4 are frequently used as markers for arteries and veins, respectively, both molecules are also co-expressed, albeit at lower levels, in cardiac capillaries. This is consistent with other reports emphasizing important roles of these molecules in sprouting vessels and capillaries ([@bib31]; [@bib63]; [@bib81]). In line with the close proximity of capillaries and cardiomyocytes, EC-specific inactivation of the *Ephb4* gene induces a hypertrophic response in the latter, which triggers heart remodeling and gives rise to a phenotype that resembles human dilated cardiomyopathy in its features and development. While EphB4 signaling is required for nutrient transport and the structural integrity of coronary capillaries, it is noteworthy that oxygen transport to the heart is not appreciably compromised despite vascular ruptures and microhemorrhaging. At the molecular level, defects in the *Ephb4*-deficient endothelium are linked to compromised caveolar function and reduced CAV1 phosphorylation, which involves the kinase Src, a known mediator of Eph receptor signaling ([@bib42]; [@bib43]). This is also consistent with a previous report showing that stimulated EphB4 associates with CAV1 and induces its phosphorylation at Tyr-14 ([@bib50]). Src-dependent phosphorylation of this residue in CAV1 promotes swelling of caveolae and their release from the plasma membrane ([@bib89]). CAV1 has also been shown to be required for signaling by EphB1, a receptor that is closely related to EphB4 ([@bib77]).

Caveolae have been associated with cardiac disease previously. CAV1 has been reported to be cardioprotective ([@bib19]) and its absence is associated with cardiac hypertrophy ([@bib16]). *Cav3* knockout mice also show a cardiomyopathy characterized by hypertrophy, heart dilation and reduced contractibility ([@bib84]). *Cav1 Cav3* double knockout animals, which completely lack caveolins because CAV2 is degraded in the absence of CAV1, develop cardiac hypertrophy and contractile failure ([@bib55]). In the healthy heart, caveolar transport is required for the membrane translocation and correct function of fatty acid translocase FAT/CD36 ([@bib59]; [@bib68]), which mediates the uptake of fatty acids. Fatty acids will be delivered to the heart muscle cells that use them to obtain about 50% to 70% of their energy ([@bib44]). Although CD36 is also expressed in the cardiomyocytes and its absence causes reduced fatty acids uptake and utilization by muscle cells ([@bib15]), it is endothelial CD36 that is critical for the uptake of fatty acids by the heart ([@bib68]). Accordingly, we found that CD36 in the plasma membrane, a localization that is critical for the function of the fatty acid translocase ([@bib29]), is profoundly reduced in cultured ECs after knockdown of *EPHB4* expression. CD36 is also reduced in Ephb4^∆EC^ coronary capillaries in vivo, whereas upregulation of CD36 in mutant cardiomyocytes might be a compensatory effect due the lack of fatty acids provided by the endothelium. In line with the results described above, CD36-deficient mice have increased fatty acid uptake in the liver and develop fatty liver similar to Ephb4^∆EC^ mutants ([@bib30]). Alterations in myocardial metabolic substrate have been related to heart failure and dilated cardiomyopathy ([@bib53]) and it is noteworthy that DCM patients show CD36 deficiency ([@bib72]).

Our findings also show that EphB4 signaling is required for maintaining the structural integrity of coronary capillaries. In this context, caveolae-mediated trafficking has been shown to be crucial for the turnover of focal adhesion points ([@bib52]). Proteins such as Vinculin or Paxillin form a molecular bridge, which couples the cytoskeleton to membrane proteins such as integrins ([@bib12]; [@bib24]) and thereby confers stiffness and mechanical stability to cells ([@bib48]). Mechanical stability is especially important in the heart, an organ where the vasculature is exposed to constant mechanical stress due to heartbeat ([@bib73]). Our results suggest that EphB4, presumably due to its role in caveolar trafficking, is required for the maintenance of focal adhesion points and thereby the structural integrity of ECs exposed to mechanical forces.

Taking all together, we propose that EphB4 and its ligand ephrin-B2 maintain fundamental properties of the endothelium in the adult heart. This function is distinct from the well-established roles of these molecules in the regulation of angiogenic blood vessel growth ([@bib2]; [@bib28]; [@bib27]; [@bib62]; [@bib80]). As the expression of EphB4 and ephrin-B2 is not confined to the cardiac vasculature, it remains unclear how these molecules can endow vessels with specialized, organ-specific properties. Previous work has shown that Eph/ephrin molecules and, in particular, ephrin-B2 are important regulators of intracellular trafficking processes such as the internalization of receptors from the cell surface ([@bib23]; [@bib25]; [@bib63]; [@bib81]). Thus, it is possible that Eph/ephrin interactions control fundamental processes, such as endocytosis and vesicular trafficking, in many different cellular settings, while the local biological outcome may strongly depend on the expression and function of specific cargo molecules. In addition, other regulators of caveolae, such as integrins ([@bib22]) might be more critical in other organs, which could contribute to local, tissue-specific properties of the vasculature.

Irrespective of the open questions outlined above, our work establishes that defects in the coronary endothelium can result in defects resembling idiopathic cardiomyopathy. Mutations in the human *EPHB4* gene are associated with various pathologies, such Capillary Malformation-Arteriovenous Malformation 2 ([@bib4]) and vein of Galen aneurysmal malformations ([@bib78]), which are known to be associated with heart failure. Accordingly, vascular defects should be considered in the diagnosis and, potentially, also treatment of cardiac disease in the future.

Materials and methods {#s4}
=====================

The Key Resources Table ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) provides a list with the mouse strains, cell line, antibodies, reagents, kits and software used for this study.

Mouse strains {#s4-1}
-------------

Mouse alleles used in this manuscript are listed including their bibliographic references. *Ephb4^flox^* ([@bib82]), *Efnb2^flox^* ([@bib32]), *Cdh5^CreERT2^* ([@bib81]), *Prox1^CreERT2^* ([@bib8]), *Rosa26R-mTmG* ([@bib51]), and *Efnb2::GFP* ([@bib20]). Mice were genotyped as previously described. All animal procedures were performed according to relevant laws and institutional guidelines, were approved by local animal ethics committees and were conducted with permissions (84--02.04.2015.A185, 84--02.04.2017.A238, 81--02.04.2019.A114) granted by the Landesamt für Natur, Umwelt und Verbraucherschutz (LANUV) of North Rhine-Westphalia.

Loss-of-function genetics {#s4-2}
-------------------------

*Cdh5^CreERT2^* and *Prox1^CreERT2^* mice were bred into a background of animals carrying *loxP*-flanked *Ephb4* and *Efnb2* gene. Experiments were performed only in male adults. Cre activity was induced by an injection of 100 µl 5 mg/ml 4-hydroxy tamoxifen (Sigma H7904) solution every day during 5 consecutive days starting at 8 weeks of age. Animals were then analyzed either at 10 weeks or 12 weeks of age.

Cardiac Magnetic Resonance Imaging (CMRI) {#s4-3}
-----------------------------------------

CMRI was performed on a 9.4 Tesla BioSpec 94/20 system (Bruker Biospin, Ettlingen, Germany) using a 35 mm quadrature birdcage coil (Rapid Biomedical, Rimpar, Germany).

Mice were anesthetized in a chamber with 3% isoflurane in oxygen (flow rate 1 L/min). During the measurements, anesthesia was maintained at 1--2% isoflurane in a mixture of medical and oxygen (3:7 at 1 L/min) through a customized anesthesia mask. Rectal temperature and breathing rate were monitored throughout the measurement and body temperature was maintained at 36--37°C using a warm water filled heating pad.

For analyzing the cardiac function and myocardial mass, a stack of contiguous short-axis slices was acquired to cover the entire right and left ventricle. A retrospectively -gated cine FLASH (IntraGate FLASH, Bruker) sequence was used with the following parameters: number of slices: 9--10, slice thickness: 1 mm, matrix: 232 × 232, field of view: 30 × 30 mm², repetition time: 5.0 ms, echo time: 2.52 ms, flip angle: 15°, number of repetitions: 200, scan time per slice: 1 min 58 s. IntraGate FLASH Data were reconstructed using Paravision software (Bruker) to obtain cinematic movies with 20 images per heart cycle and slice.

The end-diastolic and end-systolic heart phase of each slice was identified visually, using the ImageJ software (Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda, Maryland, USA, <https://imagej.nih.gov/ij/>, 1997--2016.). End-diastolic and end-systolic stacks were assembled, and analyzed using the Amira software (Visage Imaging GmbH, Berlin, Germany). Volume and wall thickness of the left and right ventricular for both time points were measured semi-automatically and the following functional cardiac parameters were calculated: wall thickness and left and right ventricular mass.

Echocardiography {#s4-4}
----------------

Mice were anaesthetized with isoflurane (1.5% in oxygen). The chest was shaved and 2D-guided B- and M-mode echocardiography was performed using a Vevo2100 (FUJIFILM VisualSonics, Inc, Toronto, Canada) equipped with an 22-55MHz linear array transducer to derive LV functional and dimensional parameters. Long- and short-axis views were obtained as described previously ([@bib70]).

Tissue processing {#s4-5}
-----------------

Heart, skeletal muscle and liver were dissected in cold PBS and fixed overnight in 4% PFA at 4**°**C. Samples were then processed for cryo-sectioning by cryo-protecting them with a series of consecutive overnight washes in PBS containing increasing concentration of sucrose (Sigma, S0389) (10%, 20% and 30%) and finally embedded in embedding solution (15% sucrose, 8% gelatin (Sigma, G1890) and 1% polyvinylpyrrolidone (pvp; Sigma, P5288) in PBS). After waiting for the embedding solution to solidify, samples were frozen at −80°C. Tibias were fixed overnight in 2% PFA at 4°C and previous to its embedding were decalcified with two consecutives overnight 15% EDTA washes at 4°C. Then cryoprotected with a single wash of 20% sucrose and 1% pvp in PBS, and finally embed as described above.

Samples were sectioned 50 µm thick in the cryostate Leica CM3050 S and collected into microscopy slides. Liver sections for Oil Red-O staining were cut 7 µm thick. After sectioning, samples were let dry overnight at room temperature and stored at −20°C.

Cryo-section immunostaining {#s4-6}
---------------------------

Before starting the immunostaining, the microscopy slide containing the samples was allowed to acquire room temperature. Slides were washed twice with PBS for 5 min to rehydrate the samples. Tissue was permeabilized with PBS containing 0.3% Triton X-100 by washing them three times 10 min and blocked for at least one hour in blocking solution (3% BSA, 0.1% Triton X-100% and 0.5% donkey serum in PBS). Primary antibodies were incubated overnight at 4°C in blocking solution. The consecutive day, four 5 min washes of PBS were performed to wash the primary antibodies. Secondary antibodies were incubated 1 hr at room temperature in PBS containing 5% of BSA. Immunostainings were imaged in a Leica SP8 confocal inverted microscope.

Primary antibodies: mouse anti-IB4-Biotin (Vector, B-1205, 1:25), WGA-tetramethylrhodamine (Invitrogen, W849, 1:100), chicken anti-GFP (2BScientific, GFP-1010, 1:100), rat anti-EphB4 (Hycult Biotechnology, HM1099, 1:100), goat anti-EphB4 (R and D Systems, AF446, 1:100) rat anti-Icam2 (BD Pharmingen, 553326, 1:100), mouse anti-SMA-cy3 (Sigma, C6198, 1:100), rat anti-PdgfrB (eBioscience, 14-1402-82, 1:100), rat anti-Ter-119 (R and D, MAB1125, 1:100), rabbit anti-Vegfr3 (ReliaTech, 102-PA22S, 1:50), rabbit anti-Collagen Type I (Millipore, AB765P, 1:100), goat anti-Collagen Type IV (Millipore, AB769, 1:100) and rabbit anti-ERG (Abcam ab110639, 1:100).

Secondary antibodies: anti-chicken Alexa Fluor-488 (Jackson Immuno Research, 103-545-155, 1:500), anti-rabbit Alexa Fluor-488 (Invitrogen, A21206, 1:500), anti-rat Cy3 (Jackson Immuno Research, 712-165-150, 1:100), anti-rabbit Alexa Fluor-546 (Invitrogen, A10040, 1:500), anti-goat Alexa Fluor-488 (Invitrogen, A11055, 1:500), anti-goat Alexa Fluor-568 (Invitrogen, A11057, 1:500) and anti-rat coupled with horseradish peroxidase (Jackson Immuno Research, 712-035-153, 1:100). The signal was then amplified using a tyramide amplification kit coupled to Cy3 (Perkin Elmer, NEL744). IB4-Biotin signal was amplified using Streptavidin Alexa Fluor-488 (Invitrogen, S11223, 1:100) and Streptavidin Alexa Fluor-647 (Invitrogen, S32357, 1:100) depending on the other secondary antibody combination. Nuclei were counterstained using DAPI (Sigma, D9542).

Stainings were quantified using Volocity software version 6.3 (Perkin Elmer).

Vibratome section immunostaining {#s4-7}
--------------------------------

Six littermate mice (3 controls and 3 mutants), 12 week-old, were anesthetized with ketamine (Zoetis, 344771)/Rompum (Bayer Healtcare, D-51368), and an incision was made along the chest cavity to expose the heart. Post perfusion with PBS and 4%PFA (PFA in PBS, 4°C, P6148, Sigma), heart, both the right and left kidneys, left lateral and right median liver were dissected out and placed in 2% PFA for 30 min. A vibrating blade microtome (VT1200, Leica) was used to section 150 µm thick sections of freshly dissected and fixed kidney and liver lobes. Sections were then refixed in 4% PFA at 4°C for 1 hr. After fixation and wash with PBS, sections were incubated in blocking buffer (0.1% BSA, 0.5% Triton-X 100, 5% donkey serum in PBS) at 4°C overnight. After five washes (0.1% Triton X-100/PBS) every 20 min, tissue slices were incubated with primary antibodies (diluted in blocking buffer) overnight at 4°C. Primary antibodies used were goat anti-CD31 (R and D Systems, AF3628, 1:100) and rat anti-ICAM2 (BD Pharmingen, 553326, 1:100). After washing to remove primary antibodies, a final overnight incubation (also at 4°C) with secondary antibodies and DAPI (diluted in blocking buffer) was carried out. Secondary antibodies used were donkey anti-goat Alexa Fluor-488 (Invitrogen, A11055, 1:500) and donkey anti-rat Alexa Fluor-647 (Jackson Immuno Research, 712-605-153, 1:500). Lastly, tissue sections were washed and then mounted using Fluoromount-G (Southern Biotech) on glass slides (with Secure-Seal spacers), placed under cover slips and sealed with nail polish at the edges.

Zeiss LSM880 confocal laser scanning microscope, in online fingerprinting mode, operating under ZEN software, was used to acquire immunofluorescence images of kidney and liver sections. Fiji ImageJ software was used for processing the images thus acquired and Illustrator (version CC 2018, Adobe) was used for compiling all the images. Within each experiment, laser excitation and confocal scanner detection were kept the same and all images were processed under identical parameters.

Western blot {#s4-8}
------------

Heart ventricles were dissected and snap frozen in liquid nitrogen. Ventricles were homogenized in Lysis buffer (20 mM Tris-HCl pH 7.4, 1 mM EDTA, cOmplete ULTRA (Roche, 05892970001), 1% NP-40, 0.1% SDS, 150 mM NaCl) with Pestle (ARgos) and clarified by centrifugation at 20000 x g for 20 min at 4°C. Protein concentration in the lysates was measured using Precision Red Advanced protein assay reagent (Cytoskeleton). Soluble supernatants were prepared in SDS-PAGE sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting after loading 20 µg of total ventricle lysate. Signal was detected using horseradish peroxidase-conjugated secondary antibodies followed by ECL Prime or ECL detection reagent (GE Healthcare).

Cultured HUVEC cells were washed twice with PBS containing 1 mM PMSF and further incubated with RIPA modified buffer (20 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.5% Triton X-100, 0.1% SDS, 0.1% Na-DOC, 2 mM EDTA, cOmplete ULTRA (Roche, 05892970001) and phosphatase inhibitor cocktail set V (EMD Millipore, 524629)) for 20 min at 4°C. Cells were scraped off and lysed by sonication. Lysates were spun down at 4°C for 10 min at full speed and protein concentration was quantified using BCA Protein Assay Kit (Pierce, 23225). Samples were prepared in SDS-PAGE sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting after loading 1.5 µg of total cell lysate.

Primary antibodies: rabbit anti-GAPDH (Cell Signaling, 2118, 1:1000), goat anti-EphB4 (R and D Systems, AF446, 1:2000), rabbit anti-phospho-Akt (Ser473) (Cell Signaling, 4060, 1:1000), rabbit anti-Akt (Cell Signaling, 4691, 1:1000), rabbit anti-p44/42 MAPK (Cell Signaling, 4695, 1:1000), rabbit anti-phospho-p44/42 MAPK (The202/Thr204) (Cell Signaling, 4370, 1:1000), mouse anti-phosphotyrosine (clone 4G10, Merck, 05--321, 1:1000), anti-rabbit Cav-1 (Cell Signaling, 3238, 1:50000), rabbit anti-phospho-Cav1 (Cell Signaling, 3251, 1:500), rabbit anti-Src (Cell Signaling, 2123, 1:1000), rabbit anti-CD36 (Abcam, ab133625, 1:1000), mouse anti-Vinculin (Sigma, V9131, 1:200) and mouse anti-beta-Actin (Santa Cruz, sc-47778, 1:6000).

Secondary antibodies: goat anti-rabbit IgG, HRP-linked whole Ab (Cell Signaling, 7074, 1:15000), sheep anti-mouse IgG, HRP-linked whole Ab (HG-Healthcare, NA931, 1:40000) and Peroxidase AffiniPure Bovine anti Goat IgG (H+L) (Jackson Immuno Research, 805-035-180, 1:15000).

Blots were quantified using ImageJ version 2.0.0 (Fiji) ([@bib65]).

Electron microscopy {#s4-9}
-------------------

Hearts from freshly killed 12 week-old mice were removed, cut into halves and fixed in 2% paraformaldehyde, 2% glutaraldehyde in 0.1M cacodylate buffer, pH 7.2. The left ventricle was cut in smaller cubes and subsequently post-fixed in 1% osmiumtetroxide, 1.5% potassiumferrocyanide in 0.1M cacodylate buffer, pH 7.2. The samples were stepwise dehydrated in ethanol, including en bloc 0.5% uranyl acetate staining during 70% ethanol incubation. Blocks were embedded in epon then sectioned ultrathin at 70 nm. Sections were collected on copper grids and stained with lead. The samples were analysed on a FEI-Tecnai 12 electron microscope (FEI, Eindhoven, The Netherlands) and representative areas were imaged with a 2 K CCD camera (Veleta, EMSIS, Münster, Germany).

Hypoxia and cell death assay {#s4-10}
----------------------------

Hypoxia was analyzed using Hypoxiprobe Plus kit-FITC (Hypoxiprobe, HP2). Animals were injected with 60 mg/kg of pimonidazole following recommended protocol. Anti-FITC-HRP signal was amplified using tyramide amplification kit coupled to Cy3 (Perkin Elmer, NEL744).

Cell death was analyzed using in situ Cell Death Detection Kit TMR red (Roche, 12156792910) according to manufacturer's instructions.

RNA-seq {#s4-11}
-------

RNA was isolated from the ventricles of 12 week-old male mice. Sequencing libraries were prepared using TrueSeq Stranded RNA LT Kit Ribo-Zero Gold (Illumina, 15032619). The resulting mRNA libraries were sequenced on a MiSeq sequencer using 2 × 75 bp paired-end MiSeq v3 chemistry (Illumina). Sequenced reads were aligned to the *Mus musculus* reference genome GRCm38 (<https://support.illumina.com/sequencing/sequencing_software/igenome.html>) using TopHat2 ([@bib37]). Then, aligned reads were used to quantify mRNA with HTSeq-count ([@bib5]). Differential gene-expression analysis between control and *Ephb4* mutant mice was performed using DESeq2 ([@bib45]). Genes were considered as differentially expressed when the FDR-adjusted *P* value was ≤ 0.05. Analysis were done using R (version 3.4.3; [@bib58]; <http://www.R-project.org/>).

All RNA--seq data have been deposited in the ArrayExpress database at EMBL-EBI ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) under the accession number E-MTAB-7686.

Mass Spectrometry (MS) {#s4-12}
----------------------

Sample preparation and LC-MS/MS analysis: Shock frozen whole mouse ventricles (n = 3 for both genotypes) were homogenized at 4°C in 1 ml of lysis buffer, containing 6M guanidinium hydrochloride (GuHCL), 5 mM tris(2-carboxyethyl) phosphine (TCEP) and 10 mM chloroacetamide (CAA) using a Cryolys Evolution tissue homogenizer (Bertin Instruments; 2 ml CKM lysing kit, 3 × 23 s at 6500 rpm; 4°C). After centrifugation (10 min, 16000 g, 4°C), protein concentrations were determined by a Bradford assay (ThermoFisher Scentific, 23236) and 2 mg of total protein per heart were subjected first to a lysyl endopeptidase predigest (enzyme: protein ratio 1:100; 3 hr, 37°C), followed by dilution to 2M GuHCl and trypsin digest overnight at 37°C (enzyme: protein ratio 1:100). Samples were then desalted using reversed-phase C18 Sep-Pak classic cartridges (Water) and lyophilized.

Peptides were dissolved in 1 ml Buffer A (10 mM NH~4~OH, pH10.2) and subjected to offline high-pH reversed-phase prefractionation using a YMC-Triart C18 column (250 × 4.6 mm) on a Platin Blue high-pressure liquid chromatography system (Knauer) using a gradient from 0--5% B (90% acetonitril, 10 mM NH~4~OH) in 1 min, from 5--39% B in 66 min, and from 39--67% in 5 min followed by a washout at 78% B and reequilibration at starting conditions. The instrument was operated at a flow rate of 1 ml/min. 47 fractions were collected, lyophilized and subjected to LC-MSMS analysis as described by [@bib9]. All samples were analysed on an Easy nLC 1200 system coupled to a Q Exactive HF mass spectrometer via a nanolectrospray source (ThermoFisher Scientific). Peptides were dissolved in buffer A (0.1% formic acid) and separated on a 25 cm column, in-house packed with 1.9 µm C18 beads (Reprosil -Pur C18 AQ, Dr. Maisch, Ammerbuch, Germany) using a gradient from 10--30% buffer B (80% acetonitril; 0.1% formic acid) within 25 min and from 30--45% in 5 min followed by a washout for 7 min at 90% B and re-equilibration at starting conditions (100% buffer A; flow rate 350 nl/min).

The Q-Exactive HF mass spectrometer was operated in data-dependent acquisition mode (spray voltage 2.1 kV; column temperature maintained at 45°C using a PRSO-V1 column oven (Sonation, Biberach, Germany)). MS1 scan resolution was set to 60,000 at m/z 200 and the mass range to m/z 350--1400. AGC target value was 3E6 with a maximum fill time of 100 ms. Fragmentation of peptides was achieved by Higher-energy collisional dissociation (HCD) using a top20 method (MS2 scan resolution 15.000 at 200 m/z; AGC Target value 1E5; maximum fill time 15 ms; isolation width 1.3 m/z; normalized collision energy 28). Dynamic exclusion of previously identified peptides was allowed and set to 30 s, singly charged and peptides assigned with charge of 6 and more were excluded from the analysis. Data were recorded with Xcalibur software (Thermo Scientific).

MS Data Analysis and label free quantification: Raw MS files were processed using the MaxQuant computional platform (version 1.6.2.6; [@bib17]). Identification of peptides and proteins was enabled by the built-in Andromeda search engine by querying the concatenated forward and reverse mouse Uniprot database (UP000000589_10090.fasta; version from 12/2015) including common lab contaminants. The allowed initial mass deviation was set to 7ppm and 20ppm in the search for precursor and fragment ions, respectively. Trypsin with full enzyme specificity and only peptides with a minimum length of 7 amino acids was selected. A maximum of two missed cleavages was allowed; the 'match between runs' option was turned on. Carbamidomethylation (Cys) was set as fixed modification, while Oxidation (Met) and N - acetylation were defined as variable modifications. For peptide and protein identifications a minimum false discovery rate (FDR) of 1% was required. All mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) ([@bib79]) via the PRIDE partner repository with the dataset identifier PXD012575.

Relative label free quantification was based on the measurements of 3 independent biological replicates for control and Ephb4^∆EC^ mice. Data processing was performed using the Perseus (version 1.6.2.1) ([@bib75]). First, we eliminated from the MaxQuant output files the reverse and contaminant hits as well as hits that were identified by a modified site only. Proteins included in the analysis had to be identified with at least two peptides, one of which had to be unique for the protein group. Intensity values were logarithmized and missing values (NaN) were replaced by imputation, simulating signals of low abundant proteins within the distribution of measured values. A width of 0.3 SD and a downshift of 1.8 SD were used for this purpose. To identify in a supervised manner the sets of proteins that significantly distinguish the control group and the Ephb4^∆EC^ proteomes, two-sample *t-*tests were performed using a p-value of 0.05. Principal component analysis was performed to project the proteome measurements into a two-dimensional data space. For this purpose, PCA was applied to all proteins that remained in the data set after filtering, transformation and imputation (6271 protein groups).

For the analysis, the primary gene identifier for each protein group was defined as the ones that represented the proteins which provided explanations for the all the peptides within a protein group.

Gene Ontology {#s4-13}
-------------

Gene ontology analysis was performed using the Enrichr platform (<http://amp.pharm.mssm.edu/Enrichr/>) ([@bib14]; [@bib39]).

Plasma analysis {#s4-14}
---------------

Extracted blood was let to coagulate for 20 min at room temperature and then centrifugated 15 min at 3000 rpm at 4°C to separate blood plasma. Samples were pooled in groups of two replicates and sent for analysis to the Institut für Veterinarmedizinische Diagnostik, GmbH in Berlin.

Liver oil Red-O {#s4-15}
---------------

Samples were gently fixed with 4% PFA for 10 min. PFA was washed with running water for 10 min and 60% isopropanol for 2 min. Samples were incubated with Oil Red-O working solution for 15 min. The working solution was made by mixing 30 ml of stock solution (0.5 g Oil Red-O (Sigma, O0625) in 100 ml isopropanol) with 20 ml water, allowed to stand 10 min and then filtered. Working solution was washed for 2 min with 60% isopropanol and rehydrated with water three times for 5 min. Sections were counterstained with hematoxilin (Sigma, MHS16) for 4 min and then washed with water until it came clear. Finally, samples were mounted with aqueous mounting medium.

Masson gold trichrome {#s4-16}
---------------------

Samples were fixed in 4% PFA and processed for cryo-sectioning. After sectioning samples were fixed again on Bouin's solution at room temperature overnight. Staining was performed using Masson Gold Trichrome kit (Roth, 3459.1) according to manufacturer's instructions.

HUVEC cell culture, siRNA transfection, Fc stimulation and inhibitor treatment {#s4-17}
------------------------------------------------------------------------------

HUVECs (ThermoFisher, C0035C) were cultured with EBM-2 endothelial cells medium (Lonza, CC-3156) supplemented with EGM-2 Single Quots (Lonza, CC-4176). Cells have not been tested for mycoplasma contamination. Cells were seeded in six well plates coated with 0.1% gelatin for protein extraction or in µ-Slide eight well (Ibidi, 80826) for staining and microscopy. Cells were transfected using Lipofectamine RNAiMAX procedure from Life technologies (Invitrogen, 13778). siRNAs: Negative control (Ambion, 4390844), *EPHB4* s244 (Ambion, 4390824) and *CAV1* (ThermoFisher, HSS141466). Four hours after transfection the medium was changed for fresh culture medium and left for 48 hr before analysis.

For Fc stimulation, cells were serum starved for 12 hr and then incubated in serum free medium containing 4 µg/ml of pre-clustered control human IgG (R and D Systems, 110-HG), human ephrin-B2/Fc (Biotechne, 7397-EB) or mouse EphB4/Fc (R and D Systems, 466-B4) proteins for 30 min. Proteins were preclustered immediately before treatment by incubating them in medium 30 min at 37°C with 0.2 µg anti-human IgG (Fc specific) (Jackson Immuno Research, 109-005-098) per µg of Fc protein at a final concentration of 10 µg/ml.

Inhibitor treatment was performed for 30 min, simultaneously with Fc stimulation or BODIPY uptake. Inhibitors used were dissolved in DMSO: LY294002 (final concentration 25 µM, Tocris, 1130), PP2 (final concentration 25 µM, Tocris, 1407) and U0126 (final concentration 10 µM, Promega, V1121). DMSO was used as vehicle control.

Immunoprecipitation {#s4-18}
-------------------

To analyze pSrc level in HUVECs, Src protein immunoprecipitation was performed. Cultured HUVECs were either treated with siRNA or serum starved for 12 hr and further stimulated with preclustered Fc proteins (see above) for 30 min. Cells were washed twice with PBS containing 1 mM PMSF before lysis, which was performed with lysis buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM EDTA, 0.2% IGEPAL CA-630, 0.5% Triton X-100, cOmplete ULTRA (Roche, 05892970001) and phosphatase inhibitor cocktail set V (EMD Millipore, 524629)). Lysis was further improved with an ultrasonic homogenizer (Sonicator UP100H). Lysates were spun down and protein concentration from the supernatants was measured using BCA Protein Assay Kit (Pierce, 23225). Equal protein amount in each lysate was further used for the immunoprecipitation. Input samples were further prepared in 2x SDS-PAGE sample buffer. Lysates were further precleared with 20 µl prewashed Protein G Sepharose 4Fast Flow resin (GE Healthcare, 17-0618-01) for 20 min at 4°C. Supernatants were incubated with rabbit anti-Src antibody (Cell Signaling, 2123, 1:50), overnight at 4°C on the rotating wheel (15 rpm). As negative control normal rabbit IgG antibody (Cell Signaling, 2729, 1:500) was used. Complexes were pulled down with 20 µl prewashed Protein G Sepharose 4Fast Flow beads by incubation at 4°C for 3 hr. Three washes with wash buffer (50 mM Tris HCl, pH 8.0, 100 mM NaCl, 50 mM EDTA, pH 8.0, 0.1% IGEPAL CA-630, cOmplete ULTRA (Roche, 05892970001) and phosphatase inhibitor cocktail set V (EMD Millipore, 524629) was performed. Beads were boiled in 2x SDS-PAGE sample buffer and immunoprecipitation (IP) supernatants were analyzed by SDS-polyacrylamide gel electrophoresis. To confirm successful immunoprecipitation, PVDF membranes were incubated with rabbit anti-Src antibody (Cell Signaling, 2123, 1:1000). Src phosphorylation was analyzed by mouse anti-phosphotyrosine antibody (clone 4G10, Merck, 05--321, 1:1000). 1.5 µg proteins were loaded for input samples.

Endothelial cell immunostaining {#s4-19}
-------------------------------

For immunostaining of HUVECs after knockdown experiments or Fc stimulation, cells were fixed with 4% PFA for 10 min. All the steps were performed at room temperature except otherwise mentioned. Cells were further incubated with 4% sucrose/PBS for 15 min, PBS rinsed and treated with 50 mM NH4Cl/PBS for 10 min. Cells were permeabilized with ice-cold 0.1% Triton X-100/PBS for 5 min at 4°C. After three PBS washes of 5 min, HUVECs were blocked with blocking buffer (4% donkey serum, 2% BSA in PBS) for 30 min. Primary antibodies were incubated in blocking buffer for 1 hr. After three PBS washes of 10 min, cells were incubated with DAPI (Sigma, D9542) and secondary antibodies for 30 min. Cells were PBS washed three times for 10 min and Fluoromount-G (Southern Biotech, 0100--01) was applied in each µ-Slide well (Ibidi, 80826). CD36 surface immunostaining was performed as described above without the cell permeabilization step.

Primary antibody used were: rabbit anti-CAV1 (Cell Signaling, 3238, 1:100), rabbit anti-pCAV1 (Y14) (Cell Signaling, 3251, 1:140), mouse anti-GM130 (BD Transduction Lab, 610822, 1:100), rabbit anti-GOLPH4 (Abcam, 28049, 1:500), goat anti-CDH5 (Biotechne, AF938, 1:70), mouse anti-CD36 (BD Biosciences, 552544, 1:100), Phalloidin Alexa Fluor-647 (Invitrogen, A22287, 1:40).

For analysis of EphB4 colocalization with pCAV1 (Y14), HUVECs were serum-starved overnight and stimulated with control human IgG/Fc (R and D Systems, 110-HG) or human ephrin-B2/Fc (Biotechne, 7397-EB) which were preclustered with goat anti-human IgG (Fc specific) (Jackson Immuno Research, 109-005-098, 10 µg/ml) for 30 min, followed by immunostaining, as described above. EphB4 immunosignal was detected with donkey anti-goat Alexa Fluor-488 (Invitrogen, A11055, 1:500).

For BSA, transferrin or BODIPY uptake experiments, HUVECs were washed twice before fixation with specific starvation medium. Immunostaining was performed as described above with minor modifications. Cells were fixed with 4% PFA for 10 min. After three PBS washes of 5 min, HUVECs were permeabilized with ice-cold 0.1% Triton X-100/PBS for 90 s on ice, with gentle shaking. Following three PBS washes of 5 min, cells were treated as described above.

HUVEC imaging was performed using Zeiss LSM780 and LSM880 confocal inverted microscopes. 10 random cells were selected per image and their shape was detected using VE-Cadherin junctional immunostaining. GM130 or GOLPH4 staining (depending on the type of experiment) were used to define the Golgi area within each cell.

Mean fluorescence intensity and normalized integrated density (Norm. IntDen) for CAV1, pCAV1 (Y14) or CD36 were calculated per whole-cell and Golgi area, using ImageJ version 2.0.0 (Fiji) ([@bib65]). Mean Fluorescence Intensity (MFI) was calculated as the ratio of Norm. IntDen to the cell area.

Fatty acid, BSA and Transferrin uptake assay {#s4-20}
--------------------------------------------

For BSA and transferrin uptake experiment HUVEC cells were serum starved in EGM-2 medium for 12 hr. For BODIPY uptake cells were serum starved in EGM2 medium containing 1% fatty-acids free BSA (Sigma-Aldrich, A9205) and 10 nM insulin (Sigma-Aldrich, I9278). Cells were incubated for 30 min with serum free medium containing BSA-555 (final concentration 4 µM, Molecular Probes, A34786) or with serum free medium containing 20 mM glucose and 1% BSA for Transferrin-488 (final concentration 50 µg/ml, Invitrogen, T13342) uptake. BODIPY C~12--~500/510 (final concentration 5 µM, Molecular Probes, D3823) uptake was performed in the above described medium. Stimulation with preclustered Fc proteins was performed simultaneously with the uptake molecule in the specific medium. After 30 minutes cells were washed with the uptake medium and were either fixed with 4% PFA for 10 min, immunostained and imaged, or directly prepared for FACS analysis. Cells were trypsinised (Sigma-Aldrich, T3924) and resuspended in FACS buffer (PBS containing 2% FCS and 2 mM EDTA). Cells were stained with DAPI (Sigma, D9542) for viability. The samples were measured using BD FACSVerse and analysed using FlowJo version 10.3.

Stretching experiments {#s4-21}
----------------------

HUVECs were grown under the same conditions described above in Bioflex 6-well plates (Flex Cell, BF-3001U). Bioflex plates were pre-treated with 0.2% gelatin in PBS. HUVEC cells were transfected with *siEPHB4* and *siControl* as described above. 48 hr after siRNA transfection cells were stretched for 24 hr in Flexercell Strain Unit, FX-4000 Tension Plus (Flex Cell). Stretching conditions were 10% sinusoidal in cycles of 1 s.

Next, cells were fixed with 4% PFA for 15 min, washed twice with PBS for 5 min and permeabilized with PBS containing 0.1% Triton X-100 for 30 min. Cells where blocked for at least one hour with blocking solution (5% donkey serum, 3% BSA and 0.1% Triton X-100 in PBS). Primary antibodies were incubated in blocking solution overnight at 4°C. After 4 PBS washes of 5 min, secondary antibodies were incubated for 1 hr in PBS containing 5% BSA. Secondary antibodies were washed twice with PBS for 5 min and nuclei were contra-stained using DAPI (Sigma, D9542). Primary antibodies: mouse anti-Vinculin (Sigma, V9131, 1:100) and rabbit anti-CDH5 (Cell Signaling, 2500, 1:100). Cytoskeleton was contra-stained using Phalloidin Alexa Fluor-647 (Invitrogen, A22287, 1:100).

HUVECs imaging was performed using Leica SP8 confocal inverted microscopes. Disruption of the HUVEC cell monolayer was quantified by measuring the area devoid of cells after stretching. To do so, we measured the black pixels in the pictures using ImageJ version 2.0.0 (Fiji) ([@bib65]). Vinculin and CDH5 colocalization in the junction area was measured by quantifying the number of voxels with both signals in Volocity software version 6.3 (Perkin Elmer).

Atomic Force Microscopy {#s4-22}
-----------------------

Force mapping was performed in EBM-2 endothelial cells medium (Lonza, CC-3156) supplemented with EGM-2 Single Quots (Lonza, CC-4176) stabilized with 10 mM HEPES (Sigma, H3537) at 37°C using a BioScope Catalyst-AFM (Bruker Nano Surfaces, Santa Barbara, California, USA) in closed-loop mode with a ramp size of 2 µm, max. force of 1nN and a tip velocity of 2.6 µm/s. A Large-Radius-Bio-Probe (Bruker AFM Probes, Camarillo, CA, USA; \'The nature of this technology is the subject of a non-provisional patent application to Bruker Nano, Inc currently pending at the United States Patent and Trademark Office.\') (tip radius 3.46 µm) was used. Spring constant of the cantilever (0.176 N/m) was determined with an interferometer (OFV-551, Polytec, Waldbronn, Germany). Deflection sensitivity was adjusted according to the SNAP procedure ([@bib64]). Each force map contained 16 × 16 force-distance cycles over an area of 150 × 150 µm. The analysis of the force--indentation curves was performed with PUNIAS software (<http://punias.free.fr/>) using the linearized Hertz model ([@bib13]).

Statistics {#s4-23}
----------

GraphPad's Prism software was used for statistical analysis of all experiments but RNA-seq and MS. Unpaired two-tailed *t* test with Welch's correction was used for comparison between two groups. For multiple comparisons, one-way ANOVA with Sidak's multiple comparisons test was used. Data is presented as scatter plots with mean ± standard error of mean (s.e.m). Differences were considered statistically significant at p\<0.05.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This is now a comprehensive study linking anatomical and functional defects in the coronary vasculature after endothelial-specific knockout of EphB4, with a molecular pathway for lipid uptake though a caveolin-mediated pathway.

**Decision letter after peer review:**

Thank you for submitting your article \"Endothelial EphB4 maintains vascular integrity and transport function in adult heart\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Harry Dietz as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is an interesting and potentially important study showing that EC-specific deletion of EphB4 leads to coronary EC branching defects, pericyte coverage, microhemorrhage, and as a result increased heart weight/tibial length, hypertrophic CMs, reduced LV chamber mass and reduced diastolic and systolic function. RNAseq and proteomics analysis and follow up studies in HUVECs and mice suggest metabolic dysfunction, specifically defects in lipid uptake via disruption of caveolin (*CAV1*) levels and trafficking.

Overall the narrative is credible. However, as the story develops around lipid uptake and caveolae dysfunction, the links between in vitro and in vivo data become uncomfortably fragmented. Reviewers identified issues surrounding the relevance of the HUVEC model, technical aspects of siRNA experiments, quantification of data, and, in particular, the missed opportunity to strengthen links between in vitro data and the mutant mouse phenotype. Since HUVECs do not exhibit the properties of heart capillary ECs, the results cannot be used to make conclusions about heart ECs without strong supporting evidence (a key theme of the paper is the difference between vascular beds). We invite the authors to address the reviewers\' comments with these criticisms in mind and specifically to provide additional data that strengthen the links between in vitro and in vivo data.

Essential revisions:

1\) TEMs are hard for the novice to interpret. They need better labels for cell types, including blood cells, and structures. Legends to Figure 2D and Figure 2---figure supplement 3 are vague. A better connection between TEM and phenotypes in vitro needs to be made (see below). It would be helpful if the differences in the TEMs were quantified. It appears that there are still many vesicles in some regions of the mutant shown on the left in Figure 2D; however, the panels shown for control do not allow the distribution to be compared.

2\) Is fibrosis a component of the cardiac condition in cKO mice? This could impact biomechanics and vessel dysfunction and fragility.

3\) Figure 4---figure supplement 2A is very unclear. What is the specific point here? VEGFR3 staining represents lymphatics. Green EphB4 is hardly visible so the impact of KO is not discernible. Why aren\'t the arrows pointing to VEGFR3+ structures?

4\) The authors used whole heart ventricle tissue for RNA-sequence and proteomics study. Without functional studies, it is difficult to assess whether EphB4 deficiency in ECs leads to dysregulation in capillary ECs, cardiomyocytes, or in both. Authors make several unvalidated assumptions based on RNA-sequence and proteomic analysis. These should be qualified.

5\) Subsection "EphB4 controls fatty acid uptake and focal adhesion in cultured ECs", second paragraph: EphB4 signaling controls PI3K and MAPK/ERK signaling and these are slightly reduced in KD HUVEC cells. However, it is unclear if this is direct or indirect. How could the authors better connect this impact with effects on *CAV1* and caveoli function? What is the biochemical impact of PI3K and AKT and ERK on *CAV1*? Can this be studied?

6\) The reduction of BSA uptake by KD HUVEC cells is slight (\~5%) -- in this sense it is not believable to show the fluorescence figure apparently indicating stronger reduction in uptake. Is this result credible? This seems to need stronger support.

7\) Figure 6C. The effect is significant but very small. Did the author knockdown a positive control gene to show the magnitude of the difference with depletion of a gene known to regulate uptake? Or alternatively, cite another paper with such analysis. This would provide confidence that the small difference with EphB4 deletion is biologically significant.

8\) Figure 6E. Although levels of *CAV1* seem to be reduced, one could argue that the strong signal in 2 of the 3 control cells shown are also peri-nuclear. This is also true of cells treated with ephrin B2-Fc. Without further quantification of intracellular compartmentalization, this is insufficient evidence for disruption of *CAV1* distribution. How does this data relate to TEM showing apparent build-up of caveolae in ECs. More data is required on localisation of *CAV1* in vitro and caveolae in vivo.

9\) The rationale for studying the role of EphB4 in regulating caveolar function in heart capillary endothelium is unclear. Src-dependent phosphorylation of caveolin-1 (Cav-1) on Y-14 is implicated in macromolecular cargo endocytosis. Did authors observe dysregulation of Cav-1 phosphorylation in ECs of EphB4^ΔEC^ mice? If so, does Src activation in heart capillary ECs require EphB4? Does EphB4 physically associated with Cav-1 in caveolar microdomains?

10\) Other experiments using immunofluorescence are sometimes missing quantification, such as in Figure 7C and D and other panels. Is the difference shown in representative images statistically different among many cells when quantified?

11\) A general but potentially important issue relating to siRNA reagents is revealed in Supplementary Figure 8-9, which show the flow plots and gating strategies. These vary considerably wrt the SSC-A/DAPI plots between experiments (Supplementary Figures 8B and 9A) and in some cases between *siControl* and siEphB4, where there seems to be an increase in DAPI+ cells in siEphB4 sample, suggesting increased cell death. The plot is very different when cells are treated with Fc or ephrin B2-Fc. What are the implications of this variability -- perhaps the changes in BSA uptake are related to the differences in cell death or stress in the culture?

12\) The CD36 data is gleaned from IF only. This should be quantified by flow. The same for Figure 7D. If robust, the latter presents a good assay for how EphrinB2/EphB4 controls lipid uptake via caveolin. Could this be exploited?

13\) The authors comment in the Discussion that EphB4 associates with *Cav1* and induces phosphorylation of Tyr-14. Can this be exploited in the current study?

14\) Have the authors considered a more direct test of their model, such as directly measuring fatty acid uptake in the heart in mutants or rescuing with CD36 re-expression?

15\) Did authors observe any vascular abnormalities in other highly vascularized organ such as lung and liver?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your revision for the article \"Endothelial EphB4 maintains vascular integrity and transport function in adult heart\" for consideration by *eLife*. Your article has been reviewed by the Reviewing Editor and overseen by Harry Dietz as the Senior Editor. No reviewers were consulted for this submission.

The narrative of the manuscript is very much improved with the addition of extensive new data and quantifications. Before acceptance, the authors should address the following points.

1\) please add arrows indicating intra-mitochondrial glycogen granules in cardiomyocytes in Figures 2D and Figure 2---figure supplement 3A-D.

2\) Please clarify in the context of the subsection "Loss of endothelial EphB4 causes heart hypertrophy" and Figure 1---figure supplement 1A-C, the overall expression patterns of EphB4 and EphrinB2. The immunofluorescence and text suggest highest staining in large veins for EphB4 but not in capillaries or arteries, whereas the efnb3-GFP is expressed in arteries and capillaries. If it is believed that EphB4 is expressed only in the venous coronary system, in the Discussion, the authors should return to this fact in light of the phenotypes discovered in vivo and the known biology around fatty acid metabolism, role of *Cav1* in endothelial cell integrity etc. This issue seems to have been glossed over in the manuscript and discussions (albeit that HUVECs were used as in vitro model). Is it possible that EphB4 is indeed expressed at lower levels in capillaries.

3\) Quantifications of pCav, *Cav1* after knockdown (KD) of EphB4 are confusing. Western blots show both *Cav1* and pCav1 are reduced after KD. Immunostainings suggest that EphB4 KD reduces *Cav1* and pCAV1 in the cytoplasm (Figure 7D), yet the quantifications do not show this. The issue of their expression in golgi is impossible to assess as the images do not show sufficient detail. Do the authors stand by this data, and if so please explain the disconnect between the western blots and immunostainings, and the quantification of expression in cell compartments in Figure 7A, D, E. Please show in revised manuscript examples of altered expression of golgi.

4\) In Figure 8A, treatment of HUVEC cells with B2/Fc induced pCav1 but not total *Cav1*. This is inhibited by PP2 (inhibitor for Src signalling). Figure 8B, C shows quantifications making the point that B2/Fc stimulate both pCav1 and pCav1/*Cav1*, and that increases in both are inhibited in the presence of PP2. Figure 8C shows the PP2 effect on pCav1 in cells. Figure 8D show that the increase in pCav1/*Cav1* with B2/Fc is not inhibited by Ly294002 and U0126 (inhibitors of PI3K and AKT). However, in Figure 8E, quantification of the increase in pCav1 in the cytoplasm versus golgi of HUVEC cells with B2/Fc, as judged by immunostaining, are shown in the presence of DMSO and inhibitors. Here, the PP2 inhibition is confirmed (PP2 also inhibits the basal level of pCav1 without B2/Fc stimulation. But LY294002 and U0126 also inhibit the B2/Fc-induced increase in pCav1, which seems to conflict with Figure 8D. There is apparently no impact on golgi localisation of pCav1. Please explain.

10.7554/eLife.45863.sa2

Author response

> \[...\] Overall the narrative is credible. However, as the story develops around lipid uptake and caveolae dysfunction, the links between in vitro and in vivo data become uncomfortably fragmented. Reviewers identified issues surrounding the relevance of the HUVEC model, technical aspects of siRNA experiments, quantification of data, and, in particular, the missed opportunity to strengthen links between in vitro data and the mutant mouse phenotype. Since HUVECs do not exhibit the properties of heart capillary ECs, the results cannot be used to make conclusions about heart ECs without strong supporting evidence (a key theme of the paper is the difference between vascular beds). We invite the authors to address the reviewers\' comments with these criticisms in mind and specifically to provide additional data that strengthen the links between in vitro and in vivo data.

We have provided in the revised version all the details relevant for the knockdown experiments and the quantification methods. We used HUVECs to study the mechanism, a cell line widely used for the in vitro studies on endothelial cells.

> Essential revisions:
>
> 1\) TEMs are hard for the novice to interpret. They need better labels for cell types, including blood cells, and structures. Legends to Figure 2D and Figure 2---figure supplement 3 are vague. A better connection between TEM and phenotypes in vitro needs to be made (see below). It would be helpful if the differences in the TEMs were quantified. It appears that there are still many vesicles in some regions of the mutant shown on the left in Figure 2D; however, the panels shown for control do not allow the distribution to be compared.

We agree. As suggested by the reviewers, we have now included labels for different cell types in Figure 2D and Figure 2---figure supplement 3.We have also quantified the total number of caveolar vesicles per capillary and the number of vesicles associated to the basolateral membrane. Quantification is now shown in Figure 2---figure supplement 3C, which also confirms that there are strong and statistically significant differences. The inclusion of the graphs will be greatly helpful for readers that are not familiar with electron micrographs or subcellular structures.

Accordingly, we have now rewritten the relevant sections of the figure legends:

"Figure 2. (D) Electron micrographs of control and *Ephb4*^∆EC^ capillaries. Bottom images are higher magnifications of boxed areas in upper panels. Arrowheads indicate accumulation of caveolar vesicles at the mutant endothelial basolateral membrane (center) and thrombocytes in a vascular rupture (right). Erythrocytes (er), thrombocytes (th), cardiomyocytes (cm) and endothelial cells (ec) are indicated."

"Figure 2---figure supplement 3. Ultrastructural analysis of *Ephb4* mutant hearts.

(A-C) Electron micrographs show details of the ventricular wall of the left ventricle. (A) Mutant endothelial cells are thickened and present irregular lining (arrowheads). \[...\] (D) Cardiomyocytes in mutant hearts show accumulation of glycogen (arrowheads) close to mitochondria. Erythrocytes (er), thrombocytes (th), cardiomyocytes (cm) and endothelial cells (ec), and pericytes (pc) are indicated."

> 2\) Is fibrosis a component of the cardiac condition in cKO mice? This could impact biomechanics and vessel dysfunction and fragility.

To assess this important question, we have performed immunostainings for collagen I and IV as well as Masson Trichrome staining of adult control and *Ephb4*^∆EC^ heart sections. These experiments did not reveal any appreciable signs of fibrosis in the mutant myocardium. The results are presented in Figure 2---figure supplement 2and mentioned in the text as follows: "It is also noteworthy that loss of EphB4 in ECs did not induce fibrosis in the mutant myocardium (Figure 2---figure supplement 2A, B)".

"Figure 2---figure supplement 2. *Ephb4* inactivation does not induce fibrosis in heart. (A) Immunohistochemistry on for Collagen I (ColI, green) and Collagen IV (ColIV, green) in transverse sections of control and *Ephb4*^∆EC^ heart showing both ventricles. \[...\] No fibrosis is observed. lv, left ventricle, rv, right ventricle."

> 3\) Figure 4---figure supplement 2A is very unclear. What is the specific point here? VEGFR3 staining represents lymphatics. Green EphB4 is hardly visible so the impact of KO is not discernible. Why aren\'t the arrows pointing to VEGFR3+ structures?

We thank the reviewers for this comment and we agree that data presentation in this figure was clearly suboptimal. The *Cdh5-CreERT2* transgenic mice used in our study are active in the endothelial cells of both blood vessels and the lymphatic vasculature. Given that both vessel types are important for cardiac function, we selectively inactivated *Ephb4* in lymphatic ECs with the help of the *Prox1-CreERT2* allele. The resulting *Ephb4*^∆LEC^ mutants retain EphB4 immunostaining in veins (indicated by arrows) but lost the signal in VEGFR3+ lymphatic vessels (indicated by arrowheads; see Figure 4---figure supplement 2). The images, data presentation and labeling have been improved in the revised manuscript and it is now much easier to understand what is shown in the figure.

> 4\) The authors used whole heart ventricle tissue for RNA-sequence and proteomics study. Without functional studies, it is difficult to assess whether EphB4 deficiency in ECs leads to dysregulation in capillary ECs, cardiomyocytes, or in both. Authors make several unvalidated assumptions based on RNA-sequence and proteomic analysis. These should be qualified.

Our RNA-seq and proteomics experiments were performed using whole heart ventricles aiming to identify changes that would help us to interpret the phenotypic and functional changes of heart function, identified by echocardiography, CMRI analysis and TEM (Figure 1 and 2).

> 5\) Subsection "EphB4 controls fatty acid uptake and focal adhesion in cultured ECs", second paragraph: EphB4 signaling controls PI3K and MAPK/ERK signaling and these are slightly reduced in KD HUVEC cells. However, it is unclear if this is direct or indirect. How could the authors better connect this impact with effects on CAV1 and caveoli function? What is the biochemical impact of PI3K and AKT and ERK on CAV1? Can this be studied?

Agree. The in vitro part of the manuscript has been revised extensively and extended (see Figures 6-8 and 9A-C). Data presented in the original Figures 6 and 7 has been replaced or moved to the supplementary figures. In the first set of new experiments, we stimulated HUVECs with recombinant, soluble proteins (namely ephrin-B2/Fc to stimulate EphB4, EphB4/Fc to trigger reverse signaling through ephrin-B2, and IgG/Fc as control) and analyzed the activation of different downstream signaling pathways. Concurrent treatment with inhibitors of Akt (LY294002), MEK (U0126), and Src (PP2) was used to validate the specificity of the observed effects. The resulting data indicate that EphB4 activation with ephrin-B2/Fc leads to the activation of Akt and Src, whereas ERK is strongly reduced (new Figure 6A, B). We have also included new data showing that Src phosphorylation is significantly reduced after *EPHB4* knockdown in HUVECs (new Figure 7). In the rest of the study, we focus mainly on Src signaling because this pathway plays a critical role in caveolar function.

Next, we investigated how EphB4 signaling affects caveolin 1 (*CAV1*) function. Here we concentrated on *CAV1* phosphorylation on tyrosine 14 (Y14), which is known to regulate caveolar trafficking, and *CAV1* localization. New Western blots prove that ephrin-B2/Fc-mediated activation of EphB4 induce an increase in phosphorylated *CAV1* (pCAV1) total protein level (new Figure 8A, B), which is absent after knockdown of *EPHB4* (new Figure 8F). Furthermore, ephrin-B2/Fc-induced *CAV1* phosphorylation is reduced by the Src inhibitor PP2 but not by U0126 or LY294002 treatment (new Figure 8B, D). pCAV1 is also reduced in *siEPHB4*-treated HUVECs or after knockdown of *CAV1*, which we have used as a positive control (new Figure 7A, C).

In another set of experiments, we show that Src inhibition reduces the levels of cytoplasmic pCAV1 but not the Golgi localized pool both without stimulation (control-Fc treatment) and after ephrin-B2/Fc treatment (new Figure 8C, E) (see also answer to question 8). In contrast, inhibition of Akt or ERK did not substantially affect *CAV1* or pCAV1 cytoplasmic and Golgi fractions.

In summary, our data establish that signaling by ephrin-B2 and EphB4 controls *CAV1* phosphorylation through Src activation.

> 6\) The reduction of BSA uptake by KD HUVEC cells is slight (\~5%) -- in this sense it is not believable to show the fluorescence figure apparently indicating stronger reduction in uptake. Is this result credible? This seems to need stronger support.

We agree with the reviewers that the flow cytometric analysis of BSA uptake revealed only a small reduction (\~5%) upon *EPHB4* KD (these data have been relocated toFigure 9---figure supplement 1). Therefore, we included quantitation of fluorescently labeled BSA per cell (3 images, 10 cells randomly selected were quantified per image). Cell shape was defined using VE-Cadherin/CDH5 junctional labeling. This approach showed a higher decrease (\~30%) in BSA uptake (as shown in new Figure 9 A, C),which is comparable to the effect seen after *CAV1* knockdown (see answer to question 7).Consistent with our previous results (see Figure 9---figure supplement 1C), transferrin uptake was not affected in *EPHB4* knockdown cells (see new data in Figure 9---figure supplement 1E, F).

> 7\) Figure 6C. The effect is significant but very small. Did the author knockdown a positive control gene to show the magnitude of the difference with depletion of a gene known to regulate uptake? Or alternatively, cite another paper with such analysis. This would provide confidence that the small difference with EphB4 deletion is biologically significant.

As suggested by the reviewers to compare the extent of albumin uptake impairment upon *EPHB4* depletion with depletion of a gene known to regulate BSA uptake, we interfered with *CAV1* expression in HUVECs. Several studies have shown a critical role for *CAV1* and caveolae in mediating albumin transcytosis in endothelial cells (e.g. Simionescu N., Int. J Cell Biol., 1981; Schubert W. et al., JBC, 2001; Ghitescu L. et al., JCB, 1986).

Our results (shown in the new Figure 9A, C) indicate that BSA uptake is similarly reduced in *EPHB4* KD and *CAV1* KD HUVECs. The quantitation graphs compare normalized integrated density per cell in control versus knockdown cells.

It was previously shown that the transcellular transport of albumin is not only mediated via caveolae, but there are also *CAV1*-independent pathways (e.g. Predescu et al., Am. J. Physiol Lung Cell Mol Physiol, 2007; Li H-H. et al., 2013). This, along with incomplete depletion of *CAV1* protein in *CAV1* KD cells, might explain the residual BSA uptake seen in our experiments.

> 8\) Figure 6E. Although levels of CAV1 seem to be reduced, one could argue that the strong signal in 2 of the 3 control cells shown are also peri-nuclear. This is also true of cells treated with ephrin B2-Fc. Without further quantification of intracellular compartmentalization, this is insufficient evidence for disruption of CAV1 distribution. How does this data relate to TEM showing apparent build-up of caveolae in ECs. More data is required on localisation of CAV1 in vitro and caveolae in vivo.

We followed the reviewer's suggestion to investigate *CAV1* intracellular compartmentalization. Indeed, we observed that *CAV1* and pCAV1 partially co-localize with Golgi markers (GM130 and GOLPH4) (new Figure 7D and 8C). Therefore, we quantified *CAV1* and pCAV1 immunosignal in Golgi and cytoplasm (excluding the intensities localized to Golgi and nuclear areas) in knockdown experiments and upon Fc protein stimulation (control Fc, ephrin-B2/Fc and EphB4/Fc). The resulting data indicate that the total level of *CAV1* and pCAV1 (as quantified by Western blotting from total cell lysates) as well as immunosignals in the Golgi area of *EPHB4* KD cells are reduced, whereas the cytoplasmic fraction is not affected. These results indicate a change in intracellular distribution of *CAV1* and pCAV1 associated with possible reduced synthesis or transport to the Golgi. These results also match well to the in vivo TEM data, which show an increased number of basolateral caveolae in *Ephb4* mutant capillary endothelium, arguing for impaired trafficking of caveolae.

We also show that ephrin-B2/Fc stimulation increases pCAV1 in total protein lysate (shown by Western blotting) and its cytoplasmic localization but not the Golgi localized fraction (new Figure 8C, E). Furthermore, the increase in phosphorylated *CAV1* protein after ephrin-B2/Fc stimulation is reduced by knockdown of *EPHB4* (new Figure 8F).

Altogether, these data indicate that EphB4 forward signaling is necessary for *CAV1* localization and phosphorylation.

> 9\) The rationale for studying the role of EphB4 in regulating caveolar function in heart capillary endothelium is unclear. Src-dependent phosphorylation of caveolin-1 (Cav-1) on Y-14 is implicated in macromolecular cargo endocytosis. Did authors observe dysregulation of Cav-1 phosphorylation in ECs of EphB4ΔEC mice? If so, does Src activation in heart capillary ECs require EphB4? Does EphB4 physically associated with Cav-1 in caveolar microdomains?

Our proteomic analysis revealed a downregulation of proteins involved in endocytic recycling in *Ephb4* mutant heart ventricles (Figure 5---figure supplement 1G) and TEM images showed that mutant ECs had an expanded cytoplasm with few vesicles, whereas caveolar vesicles accumulate along the basolateral membrane (new Figure 2D and Figure 2---figure supplement 3A-D). Prompted by these findings, we decided to investigate the link between EphB4 and *CAV1*, one of the main components of caveolae. Our in vitro data (see detailed answers to questions 5-8 above) indicate that EphB4 regulates caveolar function in a Src and *CAV1*-dependent fashion.

While we do not have direct data on Src phosphorylation in cardiac ECs in vivo, our findings on the link between EphB4, Src and *CAV1* are consistent with recent preprint showing that EphB1, a related Eph receptor, binds the *CAV1* scaffold domain in cultured ECs (Tiruppathy C. et al., bioRxiv, 2019). EphB1 activation by ephrin-B1 resulted in uncoupling of EphB1 from *CAV1*, which allowed autophosphorylation of EphB1 on Y600, followed by Src binding to EphB1. This resulted in Src activation with further downstream phosphorylation of *Cav1* on Y14. Furthermore, the authors demonstrated that EphB1 / *Cav1* interaction was required for signaling caveolae-mediated endocytosis and deletion of *Ephb1* in mice severely depleted caveolae numbers. Consequently, the internalization of Alexa Fluor-594 labeled bovine serum albumin tracer (Alexa-594 BSA) was 4-fold reduced in *EphB1*^−/−^-EC compared to WT ECs. Based on previous work, EphB1 and the ligand ephrin-B1 are, unlike ephrin-B2 and EphB4, not important for the regulation of EC function in vivo. Nevertheless, the mechanistic findings in cultured cells are consistent in both studies.

To investigate if EphB4 and *CAV1* colocalize in microdomains, we stimulated cells with control Fc or ephrin-B2/Fc chimeric proteins. After 30 minutes of stimulation with ephrin-B2/Fc, EphB4 partially co-localizes with pCAV1 in intracytoplasmic microdomains and at cellular junctions (new Figure 6C). These results are similar to the data obtained by Muto and colleagues who showed that stimulated EphB4 associates with *CAV1* (Muto et al., 2011). In the current study, we did not perform experiments to prove that EphB4 needs to physically interact with *CAV1* and, instead, it is entirely feasible that EphB4-dependent Src activation upregulates pCAV1 without direct binding between EphB4 and *CAV1*.

Despite of these open questions, which will be surely the subject of future studies, our data link EphB4 signaling to caveolar function and, as we show in Figure 9A-Cthe uptake of albumin and fatty acids by ECs.

> 10\) Other experiments using immunofluorescence are sometimes missing quantification, such as in Figure 7C and D and other panels. Is the difference shown in representative images statistically different among many cells when quantified?

We agree and we performed detailed quantitation (as shown in Figure 7, 8, 9; Figure 8---figure supplement 1 and Figure 9---figure supplement 1) and present the statistical significance in the figures and source file). Figure 7C and D from the original submission were replaced by new data shown in Figure 9 and Figure 9---figure supplement 1.

> 11\) A general but potentially important issue relating to siRNA reagents is revealed in Supplementary Figure 8-9, which show the flow plots and gating strategies. These vary considerably wrt the SSC-A/DAPI plots between experiments (Supplementary Figures 8C and 9A) and in some cases between siControl and siEphB4, where there seems to be an increase in DAPI+ cells in siEphB4 sample, suggesting increased cell death. The plot is very different when cells are treated with Fc or ephrin B2-Fc. What are the implications of this variability -- perhaps the changes in BSA uptake are related to the differences in cell death or stress in the culture?

We have grouped the flow plots and gating strategies from all uptake experiments into the new Figure 9---figure supplement 1. We understand the reviewer's concern, but there are no experimental differences between the *siControl* and *siEPHB4* treated cells within the same type of experiment. However, the SSC-A / DAPI flow plots are different due to the fact that experiments were not all performed simultaneously and cells were exposed to different tracers (BSA-555 / Transferrin-488 / BODIPY C~12~-500/510), which involved different compensation setups and gating strategies for different fluorophores (PE / FITC) in combination with DAPI gating.

> 12\) The CD36 data is gleaned from IF only. This should be quantified by flow. The same for Figure 7D. If robust, the latter presents a good assay for how EphrinB2/EphB4 controls lipid uptake via caveolin. Could this be exploited?

We have now quantified the immunofluorescence signal of CD36 in cytoplasm and Golgi per cell (new Figure 7B-E, 8G and Figure 8---figure supplement 1) and have evaluated CD36 levels as well as its change in localization upon different treatments (knockdown of *EPHB4* or *CAV1* or Fc stimulation +/- inhibitors treatments). We found no evidence for co-localization of EphB4 and CD36 (data not shown) but knockdown of *EPHB4* or *CAV1* and PP2 treatment affect its subcellular distribution of the fatty acid translocase in vitro. Nevertheless, our data indicate that fatty acid uptake is strongly reduced upon *EPHB4* (or *CAV1*) knockdown, which is consistent with the phenotypic alterations in *Ephb4* mutant hearts in vivo.

in vivo, the effect of *Ephb4* loss-of-function on CD36 is more dramatic andresults in decreased CD36 in ECs and increased CD36 levels in cardiomyocytes, probably as a compensatory response (new Figure 9). In conjunction with this, RNA-seq and proteomics data point to a role of EphB4 regulating heart metabolism. Thus, RNA-seq analysis revealed that genes related to the regulation of carbohydrate metabolism and to the positive regulation of glycolysis were upregulated in mutant samples. In addition, MS analysis of heart ventricles indicated un upregulation of fatty acid catabolic processes accompanied by a downregulation of endocytic recycling. These data indicate that *Ephb4* mutants have defects in transport processes and a metabolic shift towards glycolysis in heart.

> 13\) The authors comment in the Discussion that EphB4 associates with Cav1 and induces phosphorylation of Tyr-14. Can this be exploited in the current study?

See our response to Essential revision \#9.

> 14\) Have the authors considered a more direct test of their model, such as directly measuring fatty acid uptake in the heart in mutants or rescuing with CD36 re-expression?

We have considered this experiment, but, unfortunately, we were not able to directly measure fatty acid uptake in vivodue to the fact that carbon-11-labeled tracers have a very short half-life of 20 minutes.

> 15\) Did authors observe any vascular abnormalities in other highly vascularized organ such as lung and liver?

We have performed immunostaining of liver and kidney sections of control and *Ephb4*^∆EC^mice and could not observe any overt changes (see new Figure 4---figure supplement 1).

> \[Editors\' note: further revisions were requested prior to acceptance, as described below.\]
>
> The narrative of the manuscript is very much improved with the addition of extensive new data and quantifications. Before acceptance, the authors should address the following points.
>
> 1\) please add arrows indicating intra-mitochondrial glycogen granules in cardiomyocytes in Figures 2D and Figure 2---figure supplement 3A-D.

We have marked by arrowheads the intra-mitochondrial glycogen granules in cardiomyocytes in Figure 2D (yellow arrowheads) and Figure 2---figure supplement 3D (white arrowheads).

> 2\) Please clarify in the context of the subsection "Loss of endothelial EphB4 causes heart hypertrophy" and Figure 1---figure supplement 1A-C, the overall expression patterns of EphB4 and EphrinB2. The immunofluorescence and text suggest highest staining in large veins for EphB4 but not in capillaries or arteries, whereas the efnb3-GFP is expressed in arteries and capillaries.

We have described EphB4 and ephrin-B2 expression pattern in the main text as shown below:

"The receptor tyrosine kinase EphB4 and its ligand ephrin-B2 are expressed in the capillary plexus of the adult coronary vasculature. In addition, EphB4 is expressed in large veins, whereas ephrin-B2 is restricted to arteries (Figure 1---figure supplement 1A, B)."

We have marked EphB4 expression in mouse cardiac capillaries with blue arrowheads in Figure 1---figure supplement A, D. Expression of EphB4 in capillaries appears indeed much lower than in veins. Moreover, EphB4 expression might seem lower than ephrin-B2, which mainly reflects that we were detecting the latter using *Efnb2::GFP* reporter mice. This results in strong nuclear GFP signal and is therefore a very sensitive method for the detection of gene expression at the *Efnb2* locus.

> If it is believed that EphB4 is expressed only in the venous coronary system, in the Discussion, the authors should return to this fact in light of the phenotypes discovered in vivo and the known biology around fatty acid metabolism, role of Cav1 in endothelial cell integrity etc. This issue seems to have been glossed over in the manuscript and discussions (albeit that HUVECs were used as in vitro model). Is it possible that EphB4 is indeed expressed at lower levels in capillaries.

We are grateful for this comment and the opportunity to clarify a few important issues. While ephrin-B2 and EphB4 are frequently used as arterial and venous markers, respectively, research done by us and others indicated that both molecules are also present in the capillary endothelium and, in fact, this might be the site where these molecules interact and control EC behavior (Sawamiphak et al., 2010; Wang et al., 2010; Groppa et al. 2018, EMBO Rep. 19: e45054). This is also supported by staining with very sensitive (LacZ) reporter alleles both for ephrin-B2 and EphB4.

Based on your comments, we have improved our discussion of EphB4 and ephrin-B2 expression, EphB4-mediated regulation of *CAV1*, and CD36 regulated fatty acid transport from endothelial cells to cardiomyocytes. A version of the article with tracked changes is submitted together with the revised file.

> 3\) Quantifications of pCav, Cav1 after knockdown (KD) of EphB4 are confusing. Western blots show both Cav1 and pCav1 are reduced after KD. Immunostainings suggest that EphB4 KD reduces Cav1 and pCAV1 in the cytoplasm (Figure 7D), yet the quantifications do not show this. The issue of their expression in golgi is impossible to assess as the images do not show sufficient detail. Do the authors stand by this data, and if so please explain the disconnect between the western blots and immunostainings, and the quantification of expression in cell compartments in Figure 7A, D, E. Please show in revised manuscript examples of altered expression of golgi.

We are grateful for this comment and we agree that the differences seen in the immunostaining experiments were not properly reflected by the quantitative analysis. Moreover, a careful analysis of pCAV1 distribution indicated that only a minor fraction (0.8% in average of the whole cell immunosignal) of the immunosignal overlaps with a Golgi marker. Furthermore, we realized that both the knockdown of *EPHB4* and *CAV1* lead to substantially increased cell size (visualized by anti-VE-Cadherin/CDH5 staining; see Figure 8---figure supplement 1A), which needs to be taken into account in our quantitation.

We have therefore reanalyzed all the relevant data, removed the graphs for IF signal in cytoplasm and Golgi, and now show mean fluorescent intensity (MFI) of pCAV1 for *EPHB4* and *CAV1* knockdown experiments (Figure 7E; Figure 9C). This approach confirms the reductions in *CAV1* and pCAV1 signals seen in *siEPHB4* and *siCAV1* treated HUVECs (Figure 7D). The relevant figures and raw data files have been updated accordingly.

The new quantitations of pCAV1 immunosignals are also consistent with the Western blotting results (Figure 7A-C) where equal amounts of protein lysate were compared between *EPHB4* KD, *CAV1* KD and control HUVECs, and the amounts of *CAV1*, pCAV1 and CD36 were normalized to GAPDH internal control.

In the quantitation of all experiments involving stimulation with ephrin-B2/Fc or EphB4/Fc fusion proteins, we show signals as normalized integrated density (Norm. IntDen) because the cell area is not significantly changed (Figure 8 and Figure 8---figure supplement 1B-D).

Finally, to gain further insight into the link between EphB4, *CAV1* and CD36, we have conducted an additional experiment, which revealed a very substantial and significant reduction of CD36 at the cell surface after *EPHB4* and *CAV1* knockdown (Figure 7D and E), whereas total CD36 remains unchanged (Figure 7B-E). Interestingly, CD36 in the Golgi, presumably reflecting newly synthesized CD36 and thereby compensatory upregulation of the fatty acid transporter, is increased in *siEPHB4* and *siCAV1* treated HUVECs (Figure 7---figure supplement 1B). As CD36 localization in the plasma membrane is critical for its transporter activity, the new findings provide a compelling explanation for the reduced uptake of BODIPY C12 and connect our data on EphB4, caveolae, Src signaling and *CAV1* phosphorylation to the metabolic alterations seen in vivo.

> 4\) In Figure 8A, treatment of HUVEC cells with B2/Fc induced pCav1 but not total Cav1. This is inhibited by PP2 (inhibitor for Src signalling). Figure 8B, C shows quantifications making the point that B2/Fc stimulate both pCav1 and pCav1/Cav1, and that increases in both are inhibited in the presence of PP2. Figure 8C shows the PP2 effect on pCav1 in cells. Figure 8D show that the increase in pCav1/Cav1 with B2/Fc is not inhibited by Ly294002 and U0126 (inhibitors of PI3K and AKT). However, in Figure 8E, quantification of the increase in pCav1 in the cytoplasm versus golgi of HUVEC cells with B2/Fc, as judged by immunostaining, are shown in the presence of DMSO and inhibitors. Here, the PP2 inhibition is confirmed (PP2 also inhibits the basal level of pCav1 without B2/Fc stimulation. But LY294002 and U0126 also inhibit the B2/Fc-induced increase in pCav1, which seems to conflict with Figure 8D. There is apparently no impact on golgi localisation of pCav1. Please explain.

In line with the answer to the previous comment, we decided to show in Figure 8E the Norm.IntDen for the whole pCAV1 immunosignal and removed the data showing quantitation of the Golgi and cytoplasmic fractions. The revised versions of Figure 8C, E show ephrin-B2/Fc stimulation leads to a significant increase in pCAV1 signal, which is reduced to 51% by PP2 administration. As pointed out in your question, PP2 also lowers pCAV1 in Ctrl Fc stimulated cells (to 63%), which is consistent with the Western blot data (Figure 8A, B) and presumably reflects contributions by endogenous ephrin-B2/EphB4 interactions or other processes controlling Src activity. The AKT inhibitor LY294002 and ERK inhibitor U0126 have no significant effect on ephrin-B2/Fc-stimulated cells relative to vehicle control (DMSO; Figure 8E) even though the response seems a little blunted. While the cause of this might be indirect (e.g. through more general alterations in cell behavior), it is clear that only PP2 has a profound and significant effect on pCAV1 signals.

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.
